

Multicolor two-photon imaging of in vivo cellular pathophysiology upon influenza virus infection using the two-photon IMPRESS

Hiroshi Ueki¹, I-Hsuan Wang¹, Dongming Zhao^{1,2}, Matthias Gunzer³ and Yoshihiro Kawaoka^{1,4,5*}

In vivo two-photon imaging is a valuable technique for studies of viral pathogenesis and host responses to infection in vivo. In this protocol, we describe a methodology for analyzing influenza virus-infected lung in vivo by two-photon imaging microscopy. We describe the surgical procedure, how to stabilize the lung, and an approach to analyzing the data. Further, we provide a database of fluorescent dyes, antibodies, and reporter mouse lines that can be used in combination with a reporter influenza virus (Color-flu) for multicolor analysis. Setup of this model typically takes ~30 min and enables the observation of influenza virus-infected lungs for >4 h during the acute phase of the inflammation and at least 1 h in the lethal phase. This imaging system, which we termed two-photon IMPRESS (imaging pathophysiology research system), is broadly applicable to analyses of other respiratory pathogens and reveals disease progression at the cellular level in vivo.

Introduction

In vivo two-photon imaging is an analytical approach that can be used to visualize cell dynamics and hemodynamics in organs or tissues of live animals. Information in real time obtained by using this approach, such as changes in cell behavior and morphology, tissue localization, and blood flow, has revealed highly sophisticated and dynamic systems of living organisms. During in vivo imaging, the blood circulation in the tissue being observed is maintained; therefore, this technique is also effective for analyzing the migration and invasion of immune cells in the inflammatory environment. Observations in physiological environments deepen our understanding of host response mechanisms under both steady-state and disease conditions.

Computed tomography, X-ray, and IVIS Spectrum (an in vivo imaging system) imaging methods have been used as non-invasive approaches; however, these techniques have low spatiotemporal resolution and have been able to estimate only the site of inflammation in an organ^{1,2}. Therefore, it is impossible to observe cellular responses of the immune system using these approaches. By contrast, a two-photon excitation laser microscope, the light source of which is a near-infrared laser that produces low damage to cells but has long-reaching depth in tissue, enables us to capture the movement of cells in living animals at high resolution. Two-photon imaging has been in use in biological science since the 1990s; it has progressed at a remarkable rate, and observation methods for various organs, including brain, liver, and lymph nodes, have been reported^{3,4}. In this protocol, we describe how to use it to image virus-infected lungs. We have previously demonstrated that this protocol works by using mice infected with mouse-adapted seasonal influenza virus (H1N1) or highly pathogenic avian influenza virus (H5N1)⁵.

Challenges when imaging the lung

The lung, which is a respiratory organ, has contact with the outside environment and is an important organ for research on immunity to infectious diseases. In the seventeenth century, Marcello Malpighi

¹Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.

²State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China. ³Institute for Experimental Immunology and Imaging, University Hospital, University Duisburg-Essen, Essen, Germany.

⁴Department of Special Pathogens, International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Tokyo, Japan. ⁵Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.

*e-mail: yoshihiro.kawaoka@wisc.edu

discovered pulmonary capillaries and alveoli in the frog lung by using optical microscopy⁶; now fluorescent reporter mice facilitate the study of disease models in conjunction with two-photon excitation microscopy (Table 1). However, a challenge encountered when imaging the lung is that it is constantly moving during respiration. The lung has been stabilized in several ways during *in vivo* observation by microscopy, including bronchus clamping, prolonged apnea, gluing, and suction^{7,8}; however, it is difficult to reduce motion artifacts due to lung respiratory movement under physiological conditions and hence to obtain high-quality images. Bronchus clamping can suppress respiratory motion artifacts of the lung lobe^{9,10}; however, it is not suitable for long-term observation because it causes severe hypoxia. Although prolonging apnea is less invasive^{11–13}, it does not allow researchers sufficient time to observe the lung for image acquisition by two-photon excitation microscopy, and the quality of the images tends to deteriorate over time. Gluing addresses the above limitations^{14,15}; however, it can induce shear force injury and inflammation, which affect the interpretation of results. A suction window, which is currently the most commonly used stabilizing system during lung imaging, achieves moderate immobilization of the lung and high-quality images^{16–19}; however, the observation period is limited to ≤ 12 h. *Ex vivo* imaging of lungs and *in vivo* imaging of trachea have also been performed as complementary methods⁸. Each of these methods has its advantages and disadvantages, and it is important to select and optimize the method best suited to the goal of the experiments and disease model.

In vivo observation of lungs has been performed using various lung disease and experimental models, including bacterial infection, allergen inoculation, tumor metastasis, and lipopolysaccharide (LPS)-induced sepsis (Table 1). However, for viral respiratory diseases, such as influenza, other than an observation in a methodology report²⁰, only analyses of the trachea *in vivo*^{21–23} and isolated lungs had been performed²⁴, with no analysis of the lung *in vivo*, until our recent publication⁵ (Table 1). Unlike *ex vivo* methods, which involve isolated or sliced lungs, *in vivo* imaging using two-photon excitation microscopy of live animals enables researchers to observe hemodynamics, migration and extravasation of immune cells, as well as interactions among immune cells during influenza virus infection. However, it is technically demanding to perform two-photon excitation microscopy of live influenza virus-infected lung, which exhibits severe inflammation, requiring the development of highly sophisticated, less invasive instruments and surgical techniques. In addition, when observing animals infected with pathogenic viruses, specialized facilities and instruments are frequently required to avoid the spread of the virus. Furthermore, because many types of immune cells infiltrate the infected lung in an inflammatory environment, it is necessary to distinguish the target immune cells from the infected cells by using fluorescent labels in the infected microenvironment. To detect multiple fluorescent signals excited simultaneously by a two-photon excitation laser, fluorochromes with different spectra and equal brightness must be selected; however, there is currently no comprehensive database of fluorescent reagents, fluorescent reporter viruses, and reporter mouse lines available for lung *in vivo* imaging. We therefore also provide a database of fluorescent dyes, antibodies, and reporter mouse lines that can be used in combination with a reporter influenza virus (Color-flu)^{25–27} for multicolor analysis under pathological conditions in this protocol.

Our system uses suction-based lung stabilization^{16,28} to improve an existing *in vivo* two-photon imaging system for influenza virus-infected lung as a model of an acute inflammatory respiratory disease⁵. We have successfully used C57BL/6 mice and transgenic mice of the C57BL/6 background (6- to 10-week-old males and females). By using our method, described in detail here, it is possible to visualize and analyze the behavior of immune cells and their interactions with infected cells during an influenza virus infection, which creates an acute inflammatory environment.

Limitations of the protocol

A limitation of two-photon excitation microscopy is that the observation depth that can be achieved is a maximum of ~ 70 μm . Therefore, we cannot observe the bronchial region. This limitation is linked to the wavelength of the infrared laser and detector capability of the microscope. However, as laser technology develops, the observation depth achievable using this method will improve.

Applications of the protocol

In this protocol, we describe the application of this methodology to influenza virus infection of the lungs because this is what we have used it for previously. This protocol could be applied not only to studies of the early stages of inflammation due to infection or other causes, but also to analyses of tissue regeneration mechanisms in lungs that are in the process of recovering from infection or other

Table 1 | Summary of the disease and experimental models used for in vivo microscopic observation of the lung

| Disease/experimental model | Technique | Animal model | Year | Ref. | Disease/experimental model | Technique | Animal model | Year | Ref. |
|-------------------------------------|-----------------------------|-------------------------|------|-----------------------------|---|-----------------|--------------|------|------|
| Steady state | Clamping | Cats, rabbits | 1925 | 48 | Hypoxia | Suction | Dogs | 1975 | 49 |
| | Window approach | Cats | 1926 | 50 | | Suction | Dogs | 1979 | 51 |
| | Manual tracking | Dogs, frogs, alligators | 1930 | 52 | | Suction | Dogs | 1981 | 53 |
| | Clamping | Rabbits, cats, dogs | 1933 | 9 | | Suction | Dogs | 1982 | 54 |
| | Window approach/curare | Cats | 1934 | 55 | | Suction | Rabbits | 1992 | 56 |
| | Suction | Cats | 1939 | 57 | | Prolonged apnea | Mice | 2008 | 12 |
| | Window approach | Dogs | 1965 | 58 | | Prolonged apnea | Mice | 2013 | 59 |
| | Suction | Dogs | 1969 | 60 | | Prolonged apnea | Rats | 1999 | 11 |
| | Suction | Dogs | 1982 | 61 | | Prolonged apnea | Rats | 1999 | 62 |
| | Suction | Dogs | 1987 | 63 | | Glue | Mice | 2010 | 14 |
| | Window approach/pancuronium | Rabbits | 1989 | 64 | | Glue | Mice | 2011 | 65 |
| | Suction | Dogs | 1992 | 66 | | Glue | Mice | 2015 | 15 |
| | Suction | Rabbits | 1993 | 67 | | Glue | Mice | 2017 | 68 |
| | Suction | Rabbits | 1994 | 69 | | LPS inoculation | Mice | 2012 | 70 |
| Suction | Dogs | 1994 | 71 | Cecal ligation and puncture | Suction | Mice | 2014 | 72 | |
| Suction | Dogs | 1995 | 73 | | Suction | Mice | 2016 | 74 | |
| Prolonged apnea | Rabbits | 1997 | 75 | | Suction | Mice | 2017 | 76 | |
| Prolonged apnea | Rabbits | 1999 | 77 | | Suction | Mice | 2019 | 78 | |
| Suction | Rabbits | 2002 | 79 | | Suction | Rats | 2000 | 80 | |
| Suction | Rats | 2005 | 81 | | Suction | Mice | 2018 | 82 | |
| Prolonged apnea | Mice | 2013 | 83 | | Suction | Mice | 2019 | 78 | |
| Suction | Mice | 2017 | 19 | | Ultra-thin stick objective | Mice | 2008 | 84 | |
| Glue | Mice | 2010 | 14 | | Clamping | Mice | 2010 | 10 | |
| Prolonged apnea | Mice | 2013 | 85 | | Suction | Mice | 2012 | 86 | |
| Motion correction | Mice | 2014 | 87 | Suction | Mice | 2019 | 88 | | |
| Prolonged apnea | Mice | 2014 | 13 | Suction | Mice | 2014 | 89 | | |
| Prolonged apnea | Mice | 2016 | 90 | Suction | Mice | 2017 | 76 | | |
| Suction | Mice | 2016 | 91 | Window approach | Rats | 1994 | 92 | | |
| Suction | Mice | 2017 | 93 | Prolonged apnea | Rats | 2001 | 94 | | |
| Bacterial infection | Suction | Mice | 2017 | 95 | Prolonged apnea | Mice | 2009 | 96 | |
| | Suction | Mice | 2018 | 97 | Suction | Rats | 2011 | 17 | |
| | Suction | Mice | 2018 | 98 | Prolonged apnea | Mice | 2012 | 70 | |
| | Suction | Mice | 2018 | 99 | Suction | Mice | 2013 | 100 | |
| | Suction | Mice | 2018 | 5 | Suction | Mice | 2015 | 101 | |
| | Suction | Mice | 2000 | 102 | Suction | Mice | 2017 | 103 | |
| | Suction | Mice | 2015 | 104 | Suction | Mice | 2019 | 105 | |
| | Suction | Mice | 2015 | 106 | Suction | Mice | 2019 | 107 | |
| | Suction | Mice | 2016 | 108 | Suction | Mice | 2019 | 107 | |
| | Suction | Mice | 2016 | 18 | Suction | Mice | 2019 | 107 | |
| Viral infection Tumor metastasis | Suction | Mice | 2016 | 109 | Suction | Mice | 2019 | 105 | |
| | Glue | Mice | 2018 | 110 | Suction | Mice | 2019 | 107 | |
| | Suction | Mice | 2017 | 95 | Acid inoculation | Mice | 2009 | 96 | |
| | Suction | Mice | 2018 | 97 | Phorbol 12-myristate 13-acetate inoculation | Rats | 2011 | 17 | |
| | Suction | Mice | 2018 | 98 | Heparinase inoculation | Mice | 2012 | 70 | |
| | Suction | Mice | 2018 | 99 | Cytokine inoculation | Mice | 2013 | 100 | |
| | Suction | Mice | 2018 | 5 | Transfusion | Mice | 2015 | 101 | |
| | Suction | Mice | 2000 | 102 | Thermal hepatic injury | Mice | 2017 | 103 | |
| | Suction | Mice | 2015 | 104 | Fibrosis | Mice | 2019 | 105 | |
| | Suction | Mice | 2015 | 106 | Cytokine inoculation | Mice | 2019 | 107 | |

injuries. The information provided will also be useful to those using two-photon imaging analysis for the evaluation of the effects of drugs and vaccines, as well as biological events in the lungs and other organs (e.g., liver, spleen)⁵. Moreover, with minor modifications, the approach could be applied to analyses of other respiratory diseases, including other infectious models (e.g., severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS)), pulmonary fibrosis, and tumor metastasis.

Materials

Biological materials

- **Mice.** We have successfully used 6- to 10-week-old C57BL/6 mice (Japan SLC, mouse line C57BL/6JmsSlc) and the following transgenic mouse lines: *CAG-ECFP* (cat. no. 004218), *Cd11c-DTR/GFP* (cat. no. 004509), *Zbtb46-GFP* (cat. no. 027618), *Csf1r-GFP* (cat. no. 018549), *Cx3cr1-GFP* (cat. no. 005582), *Ncr1-GFP* (cat. no. 022739), *Clec9a-GFP* (cat. no. 017696), *Sftpc-GFP* (cat. no. 028356), *Cd11c-Cre* (cat. no. 008068), *Zbtb46-Cre* (cat. no. 028538), *Cx3cr1-Cre* (cat. no. 025524), *Cx3cr1-CreER* (cat. no. 020940), *Cd8a-Cre* (cat. no. 008766), *Cd4-CreER* (cat. no. 022356), *Cd19-Cre* (cat. no. 006785), *Mcpt8-Cre* (cat. no. 017578), *loxP*-flanked *R26-tdTomato* (Ai14) (cat. no. 007914), *R26-EYFP* (cat. no. 006148), and *R26-mT/mG* (cat. no. 007676) mice, which can be obtained from the Jackson Laboratory. *CAG-Cre* mice can be obtained from J. Miyazaki (Osaka University Graduate School of Medicine)²⁹. *LysM-GFP* mice can be obtained from T. Graf (Albert Einstein College of Medicine)³⁰. *Sftpc-CreER* mice can be obtained from B.L.M. Hogan (Duke University Medical Center)³¹. *Ly6g-Cre* (Catchup) mice can be obtained from M.G.³². *R26-mTFPI* mice can be obtained from I. Imayoshi (Kyoto University)³³. Cre strains were bred to *R26-tdTomato*, *R26-EYFP*, *R26-mTFPI*, or *R26-mT/mG* mice. *Sftpc*^{CreER/+};*R26*^{tdTomato/+} mice, *Sftpc*^{CreER/+};*R26*^{mTmG/+} mice, *Sftpc*^{CreER/+};*R26*^{tdTomato/+};*Cx3cr1*^{GFP/+} mice and *Cx3cr1*^{CreER/+};*R26*^{tdTomato/+} mice were intraperitoneally injected with 1 mg of tamoxifen for 5 d. *Cd4*^{CreER/+};*R26*^{tdTomato/+} mice and *Cd4*^{CreER/+};*R26*^{mTmG/+} mice were intraperitoneally injected with 5 mg of tamoxifen for 5 d **! CAUTION** All animal care and experiments must conform to the guidelines for animal experiments of the relevant government and institution. All our animal care and experiments conformed to the guidelines for animal experiments of the University of Tokyo and were approved by the animal research committee of the University of Tokyo (PA17-31 and PA17-17).
- **Viruses.** We have used MA-eCFP-H5N1, MA-Cerulean-H5N1, MA-eGFP-H5N1, MA-Venus-H5N1, and MA-mCherry-H5N1 (A/Vietnam/1203/2004[H5N1]); and MA-eCFP-PR8, MA-Cerulean-PR8, MA-eGFP-PR8, MA-Venus-PR8, and MA-mCherry-PR8 (A/Puerto Rico/8/34[H1N1]), which express a fluorescent reporter protein (eCFP, Cerulean, eGFP, Venus, or mCherry) fused to the NS1 protein. Viruses were generated by using reverse genetics^{25–27}. Virus strains should be propagated in Madin-Darby canine kidney (MDCK) cells. The MDCK cell line we used was obtained from R.G. Webster (St. Jude Children's Research Hospital). DNA fingerprinting showed that this cell line has the same origin as one obtained from ATCC (cat. no. CCL-34, RRID:CVCL_0422) **! CAUTION** All viruses and infected animals should be handled in accordance with your institution's biosafety regulations. All work on highly pathogenic avian influenza viruses must be performed under biosafety level 3 (BSL3) regulations. Accordingly, all our in vivo imaging studies were performed in the BSL3 facility at the University of Tokyo (Tokyo, Japan), which is approved for such use by the Ministry of Agriculture, Forestry, and Fisheries of Japan **▲ CRITICAL** The cells should be regularly checked to ensure that they are not contaminated with mycoplasma.

Reagents

▲ CRITICAL Although the suppliers used for all reagents are provided, alternative reagents are available in most cases. All reagents should be stored according to the manufacturer's recommendations. For aliquot sizes for reagents, see the 'Reagent setup' section.

- Sterile phosphate buffered saline (PBS, pH 7.4; made in-house)
- Sterile saline solution (NaCl, 0.9% (wt/vol); made in-house)
- Dimethyl sulfoxide, sterile-filtered (DMSO; Nacalai Tesque, cat. no. 13408-64) **! CAUTION** DMSO readily penetrates the skin; wear rubber gloves and protective eye goggles.
- Sunflower seed oil (Sigma-Aldrich, cat. no. 88921)
- Ethanol (99.5%; FujiFilm Wako Pure Chemical, cat. no. 057-00456) **! CAUTION** Ethanol is highly flammable and may cause eye irritation. Handle it appropriately.
- Tamoxifen (Sigma-Aldrich, cat. no. T5648)

- Isoflurane (MSD Animal Health) **! CAUTION** Isoflurane is an anesthetic gas associated with adverse health outcomes. It should be used in a well-ventilated room or with another appropriate removal system. Store it in a locked drawer at room temperature (18–25 °C).
- Sevoflurane (Maruishi Pharmaceutical) **! CAUTION** Sevoflurane is an anesthetic gas associated with adverse health outcomes. It should be used in a well-ventilated room or with another appropriate removal system. Store it in a locked drawer at room temperature.

Fluorescent reagents ! CAUTION Fluorescent reagents can be harmful. They should be handled according to the manufacturer's instructions while wearing proper protective clothing

▲ CRITICAL Choose fluorescent reagents as required for your experiment.

- Cascade Blue-conjugated dextran (10,000 molecular weight (MW); Invitrogen, cat. no. D1976)
- Fluorescein isothiocyanate (FITC)-conjugated dextran (4,000 MW; Sigma-Aldrich, cat. no. 46944)
- FITC-conjugated dextran (10,000 MW; Invitrogen, cat. no. D1820)
- FITC-conjugated dextran (40,000 MW; Invitrogen, cat. no. D1845)
- FITC-conjugated dextran (70,000 MW; Sigma-Aldrich, cat. no. 46945)
- Texas Red-conjugated dextran (3,000 MW; Invitrogen, cat. no. D3328)
- Texas Red-conjugated dextran (10,000 MW; Invitrogen, cat. no. D1863)
- Texas Red-conjugated dextran (70,000 MW; Invitrogen, cat. no. D1864)
- Qtracker 655 vascular labels (Invitrogen, cat. no. Q21021MP)
- Qdot 655 wheat germ agglutinin (WGA) conjugate (Invitrogen, cat. no. Q12021MP)
- Calcein AM solution (Sigma-Aldrich, cat. no. C1359)
- SYTOX Blue nucleic acid stain (Invitrogen, cat. no. S11348)
- SYTOX Green nucleic acid stain (Invitrogen, cat. no. S7020)
- SYTOX Orange nucleic acid stain (Invitrogen, cat. no. S11368)
- Propidium iodide (Invitrogen, cat. no. P1304MP)
- DAPI (4',6'-diamidino-2-phenylindole, dilactate; Invitrogen, cat. no. D3571)
- Hoechst 33342, trihydrochloride, trihydrate (Invitrogen, cat. no. H3570)
- Pan caspase (FAM-VAD-FMK) in vivo probe, green (Vergent Bioscience, cat. no. 20100)
- CellROX Green Reagent (Invitrogen, cat. no. C10444)
- CellROX Orange Reagent (Invitrogen, cat. no. C10443)
- CellROX Deep Red Reagent (Invitrogen, cat. no. C10422)
- LysoTracker Blue DND-22 (Invitrogen, cat. no. L7525)
- LysoTracker Green DND-26 (Invitrogen, cat. no. L7526)
- LysoTracker Red DND-99 (Invitrogen, cat. no. L7528)
- LysoTracker Deep Red (Invitrogen, cat. no. L12492)
- MitoTracker Orange CMTMRos (Invitrogen, cat. no. M7510)
- MitoTracker Red CM-H₂Xros (Invitrogen, cat. no. M7513)
- MitoTracker Red FM (Invitrogen, cat. no. M22425)
- Rhodamine 6G (Sigma-Aldrich, cat. no. 252433)
- Tetramethylrhodamine, ethyl ester, perchlorate (TMRE; Invitrogen, cat. no. T669)
- FluoSpheres polystyrene microspheres (1.0 μm, red fluorescent; Invitrogen, cat. no. F13083)
- SiR-actin (Cytoskeleton, cat. no. CY-SC001)
- SiR-tubulin (Cytoskeleton, cat. no. CY-SC002)
- PKH26 Red Fluorescent Cell Linker Kit (Sigma-Aldrich, cat. no. PKH26PCL)
- FITC-conjugated anti-mouse Ly-6G antibody (BioLegend, cat. no. 127606, RRID: AB_1236494)
- Alexa Fluor 488-conjugated anti-mouse Ly-6G antibody (BioLegend, cat. no. 127626, RRID: AB_2561340)
- DyLight 488-conjugated anti-mouse Ly-6G antibody (Leinco Technologies, cat. no. L287, RRID: AB_2810281)
- PE-conjugated anti-mouse Ly-6G antibody (BD Biosciences, cat. no. 551461, RRID: AB_394208)
- Alexa Fluor 594-conjugated anti-mouse Ly-6G antibody (BioLegend, cat. no. 127636, RRID: AB_2563207)
- Alexa Fluor 647-conjugated anti-mouse Ly-6G antibody (BioLegend, cat. no. 127610, RRID: AB_1134159)

Equipment

- Dark microtubes, (1.5 ml; Watson, cat. no. 131-915)
- Microsurgery straight scissors (13.5 cm; BRC, cat. no. 64152075)
- Microsurgery straight iris scissors (11.0 cm; BRC, cat. no. 64122001)
- Microsurgery hooked forceps (12.7 cm; BRC, cat. no. 64121044)
- Microsurgery bulldog forceps (BRC, cat. no. 70052-30CII/R)
- Tracheal cannula (1.1 × 32 mm; i.d., 0.80 mm; Nipro, cat. no. 09-043)
- Insulin syringes (0.5 ml, 100 U, 30 gauge × 10 mm; Nipro, cat. no. 08277)
- Pasteur pipettes (BD Falcon, cat. no. 357575)
- Customized surgical retractor (made in-house)
- Thoracic suction window (Sakura Seiki, custom made)
- Stage for mounting a thoracic suction window (Sakura Seiki, custom made)
- Suction regulator (Iwaki, cat. no. 1450050)
- Cover glass (Matsunami Glass, cat. no. C013001)
- Hot plate (Hipet, cat. no. 4977007036379)
- Adhesive tape (Yamato, cat. no. NO200-19)
- Customized microscope stage (Narishige, custom made)
- Confocal microscope system (Zeiss, model no. LSM 780 NLO)
- Infrared laser (Coherent, model no. Chameleon Vision II)
- 20× water immersion lens (Zeiss, Plan-Apochromat model)
- Beam-pointing stabilizer (TEM Messtechnik, model no. Aligna 4D system)
- High-efficiency particulate air (HEPA) filters (Vacushield; Pall, cat. no. 4402)
- Artificial ventilator (Shinano, cat. no. SN-480-7)
- Airway pressure monitor (Shinano)
- Gas anesthesia vaporizer (Shinano, cat. no. SN-487-OT)
- Mouse anesthesia induction chamber (Shinano, cat. no. SN-487-85-02)
- Mouse anesthesia mask (Shinano, cat. no. SN-487-70-08)
- Parafilm (Laboratory & Medical Supplies, cat. no. PM-996)
- Positive pressure mask (Versaflo Faceshields; 3M, cat. no. TR-300-HKL and TR-3712N)
- Tyvek suit (DuPont, cat. no. SoftWear III)
- Surgical gloves (SIAM OKAMOTO, cat. no. OM-100)
- Small glass window (Thorlabs, cat. no. WG12012-B)
- Planar window, RS seal (Roxtec, cat. no. RS 100 AISI 316 woc/SLFRS 100 AISI 316)
- Pulse oximeter (Kent Scientific, model. no. LabOx-1)

Software

- CellProfiler (Broad Institute: <https://cellprofiler.org/>)
- MATLAB (MathWorks: <https://www.mathworks.com/products/matlab.html>)
- Prism 6 software (GraphPad: <https://www.graphpad.com/scientific-software/prism/>)
- ImageJ (NIH: <https://imagej.nih.gov/ij/>)
- TrackMate³⁴, a plugin for ImageJ (NIH: <https://imagej.net/TrackMate>)

Reagent setup

▲ CRITICAL All reagents should be prepared under sterile conditions. Fluorescent reagents should be protecting from light during the setup procedure because they are light sensitive.

Tamoxifen solution

To prepare 10 mg/ml of tamoxifen solution in sunflower seed oil, dissolve 100 mg of tamoxifen in 1 ml of ethanol (99.5%) and add 9 ml of sunflower seed oil. After adding the ethanol and sunflower seed oil, mix well by vortexing and sonication. This solution can be stored in a refrigerator (2–8 °C) for a week. **! CAUTION** Tamoxifen powder should be handled in a hood. To avoid inhalation and contact with skin, wear rubber gloves and a surgical mask.

Fluorescent dextran

Prepare a solution at a concentration of 2 mg/ml in sterile 1× PBS or saline, make aliquots in 1.5-ml microtubes, and store them in a refrigerator (2–8 °C) for up to 2 weeks. Inject 50 µl (100 µg) of fluorescent dextran i.v. per mouse.

Qtracker 655 vascular labels

Immediately before use, add 5 μl of the stock solution to 95 μl of sterile 1 \times PBS or saline to make 100 μl total and inject 50 μl i.v. at a concentration of 0.1 μM .

FluoSpheres polystyrene microspheres

Prepare a solution at a concentration of 1×10^8 beads/ml in sterile 1 \times PBS or saline, make aliquots of the solution in dark 1.5-ml microtubes, and store them in a refrigerator (2–8 $^{\circ}\text{C}$) for long periods (~3 months). Immediately before use, mix well and inject 50 μl i.v. per mouse.

Qdot 655 WGA

Immediately before use, add 5 μl of the stock solution to 95 μl of sterile 1 \times PBS or saline to make 100 μl total and i.v. inject 50 μl .

Calcein AM solution

Prepare a solution at a concentration of 100 μM in sterile 1 \times PBS or saline, dispense the solution into dark 1.5-ml microtubes, and store them in a refrigerator (2–8 $^{\circ}\text{C}$) for up to 2 weeks. Inject 50 μl of fluorescent dextran i.v. per mouse.

SYTOX Blue, Green, and Orange

Divide the 5 mM DMSO stock solution into dark 1.5-ml microtubes and store them at -20°C for up to 3 months. Immediately before use, prepare a solution at a concentration of 50 μM in sterile 1 \times PBS or saline and i.v. inject 50 μl per mouse.

Propidium iodide

Prepare a solution at a concentration of 100 mM in sterile 1 \times PBS or saline, dispense the solution in dark 1.5-ml microtubes, and store them at -20°C for up to 3 months. Immediately before use, prepare a solution at a concentration of 1 mM in sterile 1 \times PBS or saline and inject 50 μl i.v. per mouse.

DAPI

Prepare a solution at a concentration of 10 mM in sterile 1 \times PBS or saline, make aliquots of the solution in dark 1.5-ml microtubes, and store them in a refrigerator (2–8 $^{\circ}\text{C}$) for up to 2 weeks. Inject 50 μl of the solution i.v. per mouse.

Pan caspase (FAM-VAD-FMK) in vivo probe

Prepare a working solution according to the vendor's manual, dissolve pan caspase in vivo probe in 5 μl of DMSO, and add 55 μl of 1 \times injection buffer (from the kit). Inject 60 μl of the solution i.v. per mouse within 1 h of preparation.

PKH26

Prepare a working solution according to the vendor's manual, dissolve 100 μl of PKH26PCL in 900 μl of ethanol and store at room temperature for up to 3 months. Immediately before use, prepare a solution at a concentration of 10 μM in sterile Dilution Buffer (from the kit) and inject 50 μl intranasally per mouse.

CellROX Green, Orange, and Deep Red

Immediately before use, add 50 μl of the stock solution to 450 μl of sterile 1 \times PBS or saline to make 500 μl total and inject 50 μl i.v. at a concentration of 250 μM .

LysoTracker Blue, Green, Red, and Deep Red

Immediately before use, add 50 μl of the stock solution to 450 μl of sterile 1 \times PBS or saline to make 500 μl total and inject 50 μl i.v. at a concentration of 100 μM .

MitoTracker Orange CMTMRos, Red CM-H2Xros, and Red FM

Immediately before use, dilute 50 μg of MitoTracker in 1 ml of DMSO and inject 50 μl i.v. at a concentration of 100 μM . **▲ CRITICAL** The MitoTracker solution should be prepared fresh each time immediately before use.

Rhodamine 6G

Prepare the solution at a concentration of 10 mM in sterile 1× PBS or saline, make aliquots in dark 1.5-ml microtubes, and store them in a refrigerator (2–8 °C) for up to 2 weeks. Immediately before use, prepare a solution at a concentration of 10 μM in sterile 1× PBS or saline and inject 50 μl i.v. per mouse.

TMRE

Prepare the solution at a concentration of 10 mM in DMSO, make aliquots in dark 1.5-ml microtubes, and store them in a refrigerator (2–8 °C) for up to 2 weeks. Immediately before use, prepare a working solution at a concentration of 1 mM in sterile 1× PBS or saline and inject 50 μl i.v. per mouse.

SiR-actin and SiR-tubulin

Prepare each solution at a concentration of 1 mM in DMSO, make aliquots in dark 1.5-ml microtubes, and store them in a refrigerator (2–8 °C) for up to 1 week. Immediately before use, prepare solutions at a concentration of 100 μM in sterile 1× PBS or saline and inject 50 μl i.v. per mouse.

Fluorescent antibody

Dilute fluorescent antibodies to a concentration of 1 μg per 10 μl with sterile 1× PBS or saline and inject 50 μl i.v. per mouse. **! CAUTION** It should be noted that antibody staining may affect the target cell behavior; for example, at a high dose (~200 μg), antibodies may neutralize cell activities and/or cause antibody-dependent cytotoxic activity^{35–37}. In our studies, we use 5 μg of antibody for brightness screening because inoculation of fluorochrome-conjugated anti-Ly-6G antibody at low doses (1–40 μg) into mice does not affect neutrophil recruitment³⁸. The contribution of Ly-6G, which is expressed predominantly on murine neutrophils, to recruitment during inflammation remains a matter of debate. It has been reported that low-dose antibody treatment inhibited Ly-6G ligation and the recruitment of neutrophils to the site of inflammation³⁹; however, a more recent study indicated that Ly-6G knockout did not affect either neutrophil differentiation or recruitment to the site of inflammation in Catchup mice³². Therefore, a low dose of anti-Ly-6G antibody is used in our protocol.

Equipment setup

Laser path adjustment system

An overview of the laser path adjustment system is shown in Fig. 1. Our two-photon excitation laser (Chameleon Vision II) unit is placed on an anti-vibration table outside the BSL3 facility. The laser beam enters the BSL3 room, where the two-photon excitation scanning microscope is located, through a window (composed of a small glass window (WG12012-B) and a planar window (RS seal)) connecting the inside and the outside of the BSL3 facility (Fig. 1c,d). The laser path connecting the laser source unit and the two-photon excitation microscope is adjusted by automated laser beam alignment and the Aligna 4D stabilization system is adjusted with two active mirrors. **! CAUTION** This system adjusts the laser path passing from the outside to the inside of the BSL3 facility for maintenance purposes, so there is no need for this setup unless you are using pathogens that require BSL3 containment. Heat is generated when the laser source unit is running, so keep the temperature and humidity constant by using air conditioning equipment. **! CAUTION** The system should be operated only by users trained to deal with unenclosed high-power invisible beams and should be placed in an appropriate enclosure with interlocking doors.

Two-photon excitation laser scanning microscopy system for in vivo imaging of virus-infected mouse lungs in a BSL3 facility

A schematic of the arrangement of the in vivo lung imaging system for virus-infected mouse is shown in Fig. 2a, and layout examples are shown in Fig. 2b–g. This in vivo lung imaging system is based on the upright microscope LSM 780 NLO system, which is equipped with four different lasers (excitation at 405, 488, 543, and 633 nm) for confocal imaging and a two-photon excitation laser (excitation at 630–1,050 nm). To be able to perform the surgical procedure on the mouse, we replaced the sample stage with a large, flat one (microscope stage for in vivo experiment) as shown in Fig. 2b,c. To efficiently excite multiple fluorescent proteins and fluorescent dyes simultaneously, the wavelength of the infrared laser should be set at 910 nm. All fluorescent spectra between the 410- and 695-nm wavelengths can be detected using a 20× water immersion lens, and we record signals in lambda image stacks (0.13 frames per s, 1,024 × 1,024 pixels) and acquire z-stack images with z-depths of




Fig. 1 | The laser path adjustment system. **a**, Schematic image of the system for correcting the laser beam path. **b**, Layout of active mirrors to adjust the laser path. **c**, The window through which the laser connecting the inside and outside of the BSL3 facility passes. **d**, Arrangement of the two-photon excitation microscope inside the BSL3 facility and the laser unit outside the BSL3 facility. Some images provided courtesy of Coherent and Zeiss.

5 μm (total of 10- μm z-depth). We perform spectral separation of the acquired lambda stacks by using the linear unmixing function of the ZEN software. Although the LSM 780 microscope system is controlled by a primary personal computer, we recommended adding >64 GB of RAM for appropriate imaging analysis.

We keep the mice on a heated stage on the sample stage and record their vital signs using a LabOx-1 pulse oximeter. To observe the lungs of the mice with a thoracotomy, we place the ventilator with an airway pressure monitor and anesthesia machine for rodents in appropriate positions on the stage. We installed high-efficiency particulate air (HEPA) filters in the exhalation duct of the ventilation system (Fig. 2b,d), and the operator wore a positive pressure mask (Versaflo Faceshields) and a Tyvek suit (Fig. 2e–g) to avoid exposure to the viruses. **! CAUTION** The wavelength and power of the excitation laser should be adjusted appropriately according to the experimental conditions. Increasing the laser power enhances target signals and enables detection of second-harmonic generation (SHG), in which structures with repeating patterns lead to the formation of a signal. SHG is a useful phenomenon for visualizing collagen fibers in the lung without staining; however, it should be noted that the




Fig. 2 | The in vivo lung imaging system for virus-infected mouse. **a**, Schematic image of the imaging system for virus-infected lungs. **b**, Placement of life support devices and lung stabilizer devices. **c**, Surgical stage. **d**, Anesthesia machine and mechanical ventilator. **e-g**, The operator wearing a Tyvek suit and a positive-pressure mask. All our animal care and experiments conformed to the guidelines for animal experiments of the University of Tokyo and were approved by the animal research committee of the University of Tokyo (PA17-31 and PA17-17). Some images in **a** provided courtesy of Zeiss.

autofluorescence of lung tissue is also enhanced under excessive excitation conditions (Supplementary Fig. 1). When using this protocol, we did not perform experiments under which SHG occurs, in order to minimize autofluorescence; it is better to adjust the laser power according to the experimental purpose. When the wavelength of the excitation laser is too short, the autofluorescence signal becomes very strong and it is difficult to observe properly. By contrast, when the laser wavelength is too long, it becomes difficult to obtain a signal because of the short excitation energy (Supplementary Fig. 2).

! CAUTION Although color separation of emission using a conventional optical band-pass filter is also available for this protocol, multispectral imaging is a useful approach for simultaneously analyzing multiple targets by eliminating tissue autofluorescence and identifying fluorescent labels with overlapping spectra^{40,41}. In vivo two-photon imaging is performed under conditions of single stimulation with a two-photon excitation laser; limitations exist regarding available fluorescent reagents/proteins for multiple labeling of target cells and lung architecture. Therefore, we recommend using a multispectral approach to produce crosstalk-free images of fluorescence with overlapping spectra that cannot be

separated by using band-pass filters. Before starting experiments, it is necessary to collect spectral signatures of the emission signal of each fluorescent reagent and protein as reference spectra under the same excitation condition as will be used in the experiment.

Thoracic suction window and surgical tools

To observe the mouse lung using an upright microscope, it is necessary to prepare a thoracic suction window to immobilize the lung. In the BSL3 facility, animal experiments must be performed while wearing two or three layers of latex gloves; therefore, the thoracic suction window was designed for easy handling, even in the BSL3 facility, and to be minimally invasive for the infected animals (Fig. 3a–c and Supplementary Fig. 3). To position a cover glass for each observation, flatten the upper surface of the thoracic suction window so that a commercially available cover glass will fit. This device is also designed to reduce concavity and convexity as much as possible so that blood containing virus cannot accumulate. Connect the thoracic suction window to an aspirator through a waste tank and a suction regulator. To prevent the spread of virus-containing aerosols, install HEPA filters between the waste tank and the suction regulator as shown in Fig. 3d.

Procedure

Infection with fluorescent influenza viruses ● Timing 10–20 min

- 1 On Day 0, intranasally inoculate C57BL/6 ('B6') mice or transgenic mice with 10^5 plaque-forming units (PFUs) of Color-flu viruses in 50 μ l of PBS under sevoflurane anesthesia. Tables 2 and 3 show the brightness levels of fluorescence of representative reporter mouse immune cells and Color-flu viruses in vivo.

! CAUTION All relevant guidelines regarding the use of animals and recombinant viruses should be followed.

▲ CRITICAL Fluorescent reporter influenza viruses (Color-flu) stably express high levels of a reporter protein in the infected cells and show comparable virulence to those of wild-type influenza viruses in mice²⁵. Depending on the experiments, modify the virus infectious dose, monitor the infected mice in the days following infection, and determine the appropriate time point for observation (e.g., when mice are infected with 10^3 PFU of MA-Venus-PR8, infected cells can be observed for up to 7 d post-infection). Of note, infected cells may not be observed if the infectious dose is too low.

▲ CRITICAL As controls for the experiment, use wild-type mice or transgenic mice that are not infected with influenza virus and administer the same fluorescently labeled antibodies and reagents as those used in the test group.

Starting up the imaging system equipment ● Timing 20–30 min

- 2 On the day of analysis, turn on the two-photon excitation laser and the Aligna 4D control unit placed outside the BSL3 facility, and verify that they are working.

▲ CRITICAL The Aligna 4D control unit needs to be kept ON.

- 3 Wearing a Tyvek suit, positive pressure mask, and gloves according to the guidelines for the BSL3 facility, enter the BSL3 facility where the imaging system is housed.

? TROUBLESHOOTING

- 4 Turn on the microscope controllers, confocal lasers, and the computer for the two-photon excitation microscope and the Aligna 4D system.
- 5 Launch the microscope control software ZEN and turn on the lasers, including the two-photon excitation laser.
- 6 Launch the Aligna 4D control software Kangoo and adjust the laser path connecting the laser source unit and the microscope (Supplementary Fig. 4).

? TROUBLESHOOTING

- 7 Wrap the hot plate with aluminum foil, turn it on, and keep it at 35 °C. Sterilize the surgical area and tools with 70% ethanol and place all instruments within easy reach.

Animal anesthesia ● Timing 2–3 min

- 8 Turn on the gas anesthesia vaporizer and supply 5% isoflurane to a mouse anesthesia induction chamber.
- 9 Anesthetize the influenza virus-infected mouse with 5% isoflurane in a mouse anesthesia induction chamber. Subsequently, transfer the mouse to the hot plate while supplying 2% isoflurane via an anesthetic mask.

? TROUBLESHOOTING




Fig. 3 | Devices to stabilize lungs. a, Surgical tools. **b,** Thoracic suction window. **c,** Setup of thoracic suction window and the holding devices. **d,** Device layout pertaining to lung stabilization.

Administration of fluorescent dyes ● Timing 5 min

10 Inject the chosen fluorescent dyes and antibodies via the retro-orbital plexus (as shown in Supplementary Video 1) using an insulin syringe. Tables 4 and 5 show the brightness levels of antibodies and fluorescence of dyes, respectively, in vivo.

! CAUTION When working with viruses in a BSL3 containment, it is not safe to use needles, so we avoid them as much as possible, which is a standard precaution in high-containment laboratories.

Table 2 | Comparison of fluorescent reporter mice for in vivo imaging using two-photon excitation microscopy

| Mouse | Published specificity | Ref. | Brightness | Note |
|--|--|-----------|--------------------------|---|
| <i>CAG^EGFP/ECFP</i> | Ubiquitous | 111 | +++ | Fluorescent signals are detectable; useful |
| <i>CAG^{Cre/+};R26^{EYFP/+}</i> | Ubiquitous | 29,112 | + | Fluorescent signals are hardly detectable |
| <i>CAG^{Cre/+};R26^{tdTomato/+}</i> | Ubiquitous | 29,42 | ++++ | Fluorescent signals are very strong |
| <i>CAG^EGFP/+;R26^{mTmG/+}</i> | Ubiquitous | 111,113 | +++ (ECFP) ++ (mTomato) | Fluorescent signals are detectable; useful |
| <i>R26^{mTmG/mTmG}</i> | Ubiquitous | 113 | +++ | Fluorescent signals are detectable; useful |
| <i>Cd11c^{DTR-GFP/+}</i> | Dendritic cells | 114 | + | Fluorescent signals are hardly detectable |
| <i>Cd11c^{Cre/+};R26^{EYFP/+}</i> | Dendritic cells, alveolar macrophages | 112,115 | + | Fluorescent signals are hardly detectable |
| <i>Cd11c^{Cre/+};R26^{tdTomato/+}</i> | Dendritic cells, alveolar macrophages | 42,115 | +++ | Fluorescent signals are detectable; useful |
| <i>Cd11c^{Cre/+};R26^{mTmG/+}</i> | Dendritic cells, alveolar macrophages (mGFP); ubiquitous other than dendritic cells and alveolar macrophages (mTomato) | 113,115 | +++ (mGFP) ++ (mTomato) | Fluorescent signals are detectable; useful |
| <i>Zbtb46^{GFP/GFP}</i> | Dendritic cells, endothelial cells | 116 | + | Fluorescent signals are hardly detectable |
| <i>Zbtb46^{Cre/+};R26^{tdTomato/+}</i> | Dendritic cells, endothelial cells | 42,117 | ++++ | Because the fluorescence signal of the endothelial cells is very strong, a bone marrow chimera is needed for immune cell observations |
| <i>Zbtb46^{Cre/+};R26^{mTmG/+}</i> | Dendritic cells, endothelial cells | 113,117 | ++++ (mGFP) ++ (mTomato) | Because the fluorescence signal of the endothelial cells is very strong, a bone marrow chimera is needed for immune cell observations |
| <i>Clec9a^{GFP/+}</i> | Dendritic cells | 118 | + | Fluorescent signals are hardly detectable |
| <i>Csf1l^{GFP/+}</i> | Macrophages | 119 | +++ | Because many cells are fluorescently labeled, it is difficult to make cell-specific observations, especially in infected lung |
| <i>Cx3cr1^{GFP/+}</i> | Macrophages, monocytes | 120 | +++ | Fluorescent signals are detectable; useful |
| <i>Cx3cr1^{Cre/+};R26^{tdTomato/+}</i> | Macrophages, monocytes | 42,121 | ++++ | Because many cells are fluorescently labeled, it is difficult to make cell-specific observations, especially in infected lung |
| <i>Cx3cr1^{CreER/+};R26^{tdTomato/+}</i> | Macrophages, monocytes | 42,121 | +++ | Fluorescent signals are detectable; useful |
| <i>LysM^{GFP/+}</i> | Neutrophils, macrophages | 30 | +++ | Because many cells are fluorescently labeled, it is difficult to make cell-specific observations, especially in infected lung |
| <i>Ly6g^{Cre/+};R26^{tdTomato/+}</i> (Catchup ^{VM:red}) | Neutrophils | 32,42 | +++ | Fluorescent signals are detectable; useful |
| <i>Ly6g^{Cre/+};R26^{mTmG/+}</i> | Neutrophils (mGFP); ubiquitous other than neutrophils (mTomato) | 32,113 | +++ (mGFP) ++ (mTomato) | Fluorescent signals are detectable; useful |
| <i>Ly6g^{Cre/+};R26^{mTmG/+}</i> | Neutrophils | 32,33 | +++ | Fluorescent signals are detectable; useful |
| <i>Ly6g^{Cre/+};R26^{mTmG/+}</i> | Macrophages, monocytes (GFP); neutrophils (Tomato) | | 32,42,120 | +++ (GFP) +++ (Tomato) |
| Fluorescent signals are detectable; useful | | | | |
| <i>Cd4^{CreER/+};R26^{tdTomato/+}</i> | CD4T lymphocytes | 42,122 | +++ | Fluorescent signals are detectable; useful |
| <i>Cd4^{CreER/+};R26^{mTmG/+}</i> | CD4T lymphocytes (mGFP); ubiquitous other than CD4T lymphocytes (mTomato) | 113,122 | +++ (mGFP) ++ (mTomato) | Fluorescent signals are detectable; useful |
| <i>Cd8^{Cre/+};R26^{tdTomato/+}</i> | CD8T lymphocytes | 42,123 | +++ | Fluorescent signals are detectable; useful |
| <i>Cd8^{Cre/+};R26^{mTmG/+}</i> | CD8T lymphocytes | 33,123 | +++ | Fluorescent signals are detectable; useful |
| <i>Cd19^{Cre/+};R26^{tdTomato/+}</i> | B lymphocytes | 42,124 | +++ | Fluorescent signals are detectable; useful |
| <i>Mcp18^{Cre/+};R26^{tdTomato/+}</i> | Basophils | 42,125 | +++ | Fluorescent signals are detectable; useful |
| <i>Ncr1^{GFP/+}</i> | NK cells | 126 | ++ | Fluorescent signals are detectable; useful |
| <i>Sftpc^{CreER/+};R26^{tdTomato/+}</i> | Type II pneumocytes | 31,42 | ++++ | Fluorescent signals are detectable; useful |
| <i>Sftpc^{CreER/+};R26^{mTmG/+}</i> | Type II pneumocytes (mGFP); ubiquitous other than Type II pneumocytes (mTomato) | 31,113 | +++ (mGFP) ++ (mTomato) | Fluorescent signals are detectable; useful |
| <i>Sftpc^{CreER/+};R26^{tdTomato/+}</i> ; <i>Cx3cr1^{GFP/+}</i> | Macrophages, monocytes (GFP); Type II pneumocytes (Tomato) | 31,42,120 | +++ (GFP) ++++ (Tomato) | Fluorescent signals are detectable; useful |
| <i>Sftpc^{GFP/+}</i> | Type II pneumocytes | 127 | ++++ | Fluorescent signals are detectable; useful |

The brightness of each fluorescent protein during in vivo lung imaging was scored as relative fluorescence intensity compared with FluoSpheres fluorescent microspheres as an internal standard. For relative intensities of 0–0.2, 0.2–0.6, 0.6–0.9, and >0.9, the brightness scores are represented as +, ++, +++, and +++++, respectively.

Table 3 | Comparison of fluorescent reporter viruses (Color-flu) for in vivo imaging using two-photon excitation microscopy

| Reporter protein | Virus name | Titer | Volume | Excitation (nm) | Emission (nm) | Brightness |
|------------------|----------------------------------|---------------------|--------|-----------------|---------------|------------|
| eCFP | MA-eCFP-PR8 MA-eCFP-H5N1 | 10 ⁵ PFU | 50 µl | 910 | 477 | + |
| Cerulean | MA-Cerulean-PR8 MA-Cerulean-H5N1 | 10 ⁵ PFU | 50 µl | 910 | 475 | +++ |
| eGFP | MA-eGFP-PR8 MA-eGFP-H5N1 | 10 ⁵ PFU | 50 µl | 910 | 507 | +++ |
| Venus | MA-Venus-PR8 MA-Venus-H5N1 | 10 ⁵ PFU | 50 µl | 910 | 528 | +++ |
| mCherry | MA-mCherry-PR8 MA-mCherry-H5N1 | 10 ⁵ PFU | 50 µl | 910 | 610 | + |

The brightness of each fluorescent protein during in vivo lung imaging was scored as relative fluorescence intensity compared with FluoSpheres fluorescent microspheres as an internal standard. For relative intensities of 0-0.2, 0.2-0.6, 0.6-0.9, and >0.9, the brightness scores are represented as +, ++, +++, and +++++, respectively.

Table 4 | Comparison of fluorochrome-conjugated antibodies for in vivo imaging using two-photon excitation microscopy

| Fluorochrome | Product name | Cat. no. | Clone | Concentration | Volume | Excitation (nm) | Emission (nm) | Brightness |
|--------------|--|---------------------------|-------|---------------|--------|-----------------|---------------|------------|
| FITC | FITC-conjugated anti-mouse Ly-6G antibody | 127606, BioLegend | 1A8 | 100 µg/ml | 50 µl | 910 | 519 | + |
| AF 488 | AF 488-conjugated anti-mouse Ly-6G antibody | 127626, BioLegend | 1A8 | 100 µg/ml | 50 µl | 910 | 519 | + |
| Dy Light 488 | DyLight 488-conjugated anti-mouse Ly-6G antibody | L287, Leinco Technologies | 1A8 | 100 µg/ml | 50 µl | 910 | 518 | + |
| PE | PE-conjugated anti-mouse Ly-6G antibody | 551461, BD Biosciences | 1A8 | 100 µg/ml | 50 µl | 910 | 578 | +++ |
| AF 594 | AF 594-conjugated anti-mouse Ly-6G antibody | 127636, BioLegend | 1A8 | 100 µg/ml | 50 µl | 910 | 617 | ++ |
| AF 647 | AF 647-conjugated anti-mouse Ly-6G antibody | 127610, BioLegend | 1A8 | 100 µg/ml | 50 µl | 910 | 668 | ND |

The brightness of each fluorochrome during in vivo lung imaging was scored as relative fluorescence intensity compared with FluoSpheres fluorescent microspheres as an internal standard. For relative intensities of 0-0.2, 0.2-0.6, 0.6-0.9, and >0.9, the brightness scores are represented as +, ++, +++, and +++++, respectively. AF, Alexa Fluor; ND, not detected.

In addition, in the BSL3 facility, animal experiments must be performed wearing two or three layers of latex gloves. Tail-vein administration is a common method; however, it is not easy to perform these procedures with so many layers of gloves. Use tweezers to hold down the mouse to make the administration route. When an infected animal is not used, an administration route can be created via the tail vein or the jugular vein.

? TROUBLESHOOTING

Surgical procedure ● Timing 10-15 min

▲ CRITICAL Before experimenting with infected animals, practice the surgical procedures with euthanized animals.

- Place the mouse on its back and tape the anterior limbs with adhesive tape (Fig. 4a).
- Using straight scissors, cut the skin beneath the chin in the middle and expose the trachea (Fig. 4b). Insert a tracheal cannula and intubate the mouse to facilitate mechanical ventilation with a ventilator (Fig. 4c). Turn on the ventilator, ventilate the mouse at a respiratory rate of 120 breaths per min, and apply positive-end expiratory pressure (PEEP; ~6 cm H₂O) and a tidal volume of ~0.5 mL. Deliver isoflurane continuously at 2% to maintain anesthesia.

! CAUTION Perform the surgery with care so as not to cut the blood vessels. If bleeding occurs, stop the bleeding with fine bulldog forceps for microsurgery.

- Place the mouse in the right lateral decubitus position and re-fix its anterior limbs with the tape (Fig. 4d). Make an incision in the skin at the left axilla using straight scissors, straight iris scissors, and hooked forceps (Fig. 4e).

! CAUTION Carefully change the mouse's position in order to avoid cannula drop off.

- Expose the left lung lobe by surgical intercostal incision between ribs 3 and 4, and keep it exposed by using retractors (Fig. 4f).

Table 5 | Comparison of fluorescent dyes for in vivo imaging using two-photon excitation microscopy

| Dye | Target | Cat. no. | Concentration | Volume | Excitation (nm) | Emission (nm) | Brightness |
|--|---------------------|---------------------------|------------------------------|--------------------|-----------------|---------------|------------|
| Dextran Cascade Blue, 10,000 MW, lysine fixable | Blood flow | D1976, Invitrogen | 25 mg/ml | 50 µl | 910 | 420 | ND |
| Fluorescein isothiocyanate-dextran average MW 4,000 | Blood flow | 46944, Sigma-Aldrich | 2 mg/ml | 50 µl | 910 | 519 | +++ |
| Dextran fluorescein, 10,000 MW, lysine fixable | Blood flow | D1820, Invitrogen | 2 mg/ml | 50 µl | 910 | 519 | +++ |
| Dextran fluorescein, 40,000 MW, lysine fixable | Blood flow | D1845, Invitrogen | 2 mg/ml | 50 µl | 910 | 519 | +++ |
| Fluorescein isothiocyanate-dextran, average MW 70,000 | Blood flow | 46945, Sigma-Aldrich | 2 mg/ml | 50 µl | 910 | 519 | +++ |
| Dextran Texas Red, 3,000 MW, lysine fixable | Blood flow | D3328, Invitrogen | 2 mg/ml | 50 µl | 910 | 615 | +++ |
| Dextran Texas Red, 10,000 MW, lysine fixable | Blood flow | D1863, Invitrogen | 2 mg/ml | 50 µl | 910 | 615 | +++ |
| Dextran Texas Red, 70,000 MW, lysine fixable | Blood flow | D1864, Invitrogen | 2 mg/ml | 50 µl | 910 | 615 | +++ |
| Qtracker 655 vascular labels | Blood flow | Q2102IMP, Invitrogen | 0.1 µM | 50 µl | 910 | 655 | +++ |
| FluoSpheres fluorescent microspheres for tracer studies | Blood flow velocity | F-13083, Molecular Probes | 1 × 10 ⁸ beads/ml | 50 µl | 910 | 605 | ++++ |
| Qdot 655 WGA | Whole cells | Q1202IMP, Invitrogen | ×20 | 50 µl | 910 | 655 | + |
| Calcein AM solution | Live cells | C1359, Sigma-Aldrich | 100 µM | 50 µl | 910 | 520 | ND |
| SYTOX Blue nucleic acid stain | Dead cells | S11348, Invitrogen | 50 µM | 50 µl | 910 | 480 | +++ |
| SYTOX Green nucleic acid stain | Dead cells | S7020, Invitrogen | 50 µM | 50 µl | 910 | 523 | +++ |
| SYTOX Orange nucleic acid stain | Dead cells | S11368, Invitrogen | 50 µM | 50 µl | 910 | 570 | +++ |
| Propidium iodide nucleic acid stain | Dead cells | P1304MP, Invitrogen | 1 mM | 50 µl | 910 | 617 | ++++ |
| DAPI nucleic acid stain | Dead cells | D3571, Invitrogen | 10 mM | 50 µl | 910 | 461 | ND |
| Hoechst 33342 | Nuclei | H3570, Invitrogen | 10 mg/ml | 50 µl | 910 | 461 | ++ |
| Cas-MAP Green in vivo fluorescent imaging probes | Apoptotic cells | 20100, Vergent Bioscience | ×1 | 60 µl | 910 | 533 | ND |
| PKH26 Red Fluorescent Cell Linker Kit for Phagocytic Cell Labeling | Phagocytic cells | PKH26PCL, Sigma-Aldrich | 10 µM | 50 µl (intranasal) | administration) | 910 | 567 |
| +++ | | | | | | | |
| CellROX Green Reagent | Oxidative stress | C10444, Molecular Probes | 250 µM | 50 µl | 910 | 520 | +++ |
| CellROX Orange Reagent | Oxidative stress | C10443, Molecular Probes | 250 µM | 50 µl | 910 | 565 | +++ |
| CellRox Deep Red | Oxidative stress | C10422, Molecular Probes | 250 µM | 50 µl | 910 | 665 | + |
| LyoTracker Blue DND-22 | Lysosomes | L7525, Molecular Probes | 100 µM | 50 µl | 910 | 422 | ND |
| LyoTracker Green DND-26 | Lysosomes | L7526, Molecular Probes | 100 µM | 50 µl | 910 | 511 | +++ |
| LyoTracker Red DND-99 | Lysosomes | L7528, Molecular Probes | 100 µM | 50 µl | 910 | 590 | ++ |
| LyoTracker Deep Red | Lysosomes | L12492, Molecular Probes | 100 µM | 50 µl | 910 | 668 | ++ |
| MitoTracker Orange CMTMRos | Mitochondria | M7510, Invitrogen | 100 µM | 50 µl | 910 | 576 | +++ |
| MitoTracker CM-H ₂ Xros | Mitochondria | M7513, Invitrogen | 100 µM | 50 µl | 910 | 599 | +++ |
| MitoTracker Red FM | Mitochondria | M22425, Invitrogen | 100 µM | 50 µl | 910 | 644 | ++ |
| Rhodamine 6G | Mitochondria | 252433, Sigma-Aldrich | 10 µM | 50 µl | 910 | 555 | +++ |
| TMRE | Mitochondria | T669, Invitrogen | 1 mM | 50 µl | 910 | 575 | +++ |
| SiR-actin | Actin | CY-SC001, SPIROCHROME | 100 µM | 50 µl | 940 | 674 | + |
| SiR-tubulin | Tubulin | CY-SC002, SPIROCHROME | 100 µM | 50 µl | 940 | 674 | ND |

The brightness of each fluorochrome during in vivo lung imaging was scored as relative fluorescence intensity compared with FluoSpheres fluorescent microspheres as an internal standard. For relative intensities of 0–0.2, 0.2–0.6, 0.6–0.9, and >0.9, the brightness scores are represented as +, ++, +++, and +++++, respectively. ND, not detected.




Fig. 4 | Surgical procedure for lung imaging. **a**, Place the mouse on its back and tape with adhesive tape. **b**, Cut the skin beneath the chin and expose the trachea. **c**, Insert a tracheal cannula. **d**, Place the mouse in the right lateral decubitus position. **e**, Make an incision in the skin at the left axilla. **f**, Expose the left lung lobe and keep it exposed by using retractors. **g**, Lower the thoracic suction window gently to immobilize the lungs of the mouse. **h**, Close-up of the thoracic suction window. **i**, Lower the objective lens to the thoracic suction window. All our animal care and experiments conformed to the guidelines for animal experiments of the University of Tokyo and were approved by the animal research committee of the University of Tokyo (PA17-31 and PA17-17).

! CAUTION Perform the surgery with care so as not to cut the blood vessels. If bleeding occurs, stop the bleeding with fine bulldog forceps for microsurgery.

▲ CRITICAL Because lungs infected with viruses often shrink, secure a large field of surgical view so that the suction window can reach it.

Table 6 | Open-source packages for image processing and analyses

| Purpose | Software | Resource | Features | Ref. |
|---------------------------------|---|--|--------------------------------|---------|
| Unmixing of lambda image stack | Hyper-Spectral Phasors | https://www.nature.com/articles/nmeth.4134 | Windows/macOS executable | 128 |
| | Orfeo ToolBox | https://www.orfeo-toolbox.org/ | Windows/macOS/Linux executable | 129 |
| Respiratory artifact correction | Spectral Unmixing Plugins | https://imagej.nih.gov/ij/plugins/spectral-unmixing.html | ImageJ plugin | 130,131 |
| | PoissonNMF | https://neherlab.org/poisson_nmf_overview.html | ImageJ plugin | 132 |
| | Imregdemons (image-processing toolbox for MATLAB) | https://www.mathworks.com/help/images/ref/imregdemons.html | MATLAB function | 133,134 |
| | Automatic image reconstruction | Algorithm described in the original paper | Algorithm | 135 |
| | Intravital microscopy artifact reduction tool (IMART) | http://www.medicine.iupui.edu/icbm/software/ | MATLAB executable | 136,137 |
| | Intravital Microscopy Toolbox | https://doi.org/10.1371/journal.pone.0053942.s020 or http://stevellacroix.crchudequebec.ca/support-visuel_en.php | ImageJ macro | 138 |
| Single-cell tracking | Galene | https://galene.flimfit.org/ | Windows/macOS executable | 139 |
| | The Tracking Tool (tTt) | https://www.nature.com/articles/nbt.3626 | Windows/macOS executable | 140 |
| | CellProfiler | https://cellprofiler.org/ | Windows/macOS executable | 141 |
| | Icy | http://icy.bioimageanalysis.org/ | Java application | 142 |
| | TrackMate | http://fiji.sc/TrackMate | ImageJ plugin | 34 |

- 15 Place the mouse beneath the objective lens and connect a device to monitor the heart rate of the mouse (we use a LabOx-1 pulse oximeter).

? TROUBLESHOOTING

Starting up the thoracic vacuum window system ● Timing 2–3 min

- 16 Turn on the aspirator connected to the thoracic suction window.
- 17 Fix the thoracic suction window to the holding block at a 90° angle and put a round cover glass on the tip of the suction device.
- ? TROUBLESHOOTING
- 18 Turn on the suction pressure regulator and adjust the suction pressure to 25–30 mmHg.

Observation of lungs infected with influenza viruses ● Timing 2–3 min

- 19 Lower the thoracic suction window gently to immobilize the mouse lungs (Fig. 4g,h). The thoracic suction window should cause the lung to stick to the cover glass because of negative pressure.
- ! CAUTION** Carefully move the suction window so as not to scratch the objective.
- 20 Position the objective lens above the thoracic window.
- 21 Put water drops on the cover glass by using a pasteur pipette and lower the objective lens to the thoracic suction window (Fig. 4i).
- 22 Double-check the general condition of the mouse and its position.

Data acquisition ● Timing 1–4 h per sample

- 23 Acquire images using the lambda mode of the ZEN software. Record time series at different frequencies according to need.

Unmixing of spectrum data and analyzing the images ● Timing 1–2 h per sample

- 24 To unmix the spectrum data, prepare a reference image of each spectrum in advance. To make a reference image, acquire each fluorescent dye or protein separately without any co-staining and analyze the single fluorescent spectrum. We use the linear unmixing module of the ZEN software for separating spectrum data; however, other commercial or open-source software is available (Table 6).

- 25 Subject unmixed time-series stacks to image registration to correct for tissue drifts and respiratory artifacts. This step is critical to certain analyses, such as long-term tracking of individual cells or subcellular structures. In some cases, a reference channel is required for determining the shift and distortion of the objects. In our studies, we use time-series stacks of blood vessels or collagens for such use, because their localizations are constant over time without substantial changes in shape or structure during the observation.
! CAUTION Some image registration algorithms may cause spatial distortion. Choose algorithms that generate corrected data suitable for your subsequent analyses, especially when examination of the shape and structure of cells and tissues is required.
- 26 Analyze the movies as required for your experiment.

Troubleshooting

Troubleshooting advice can be found in Table 7.

| Step | Problem | Possible reason | Solution |
|------|---|---|--|
| 3 | Difficulty handling mice in BSL3 facility | Normal gloves are not suitable for working in a BSL3 facilities | To perform detailed work in a BSL3 facility, the outermost gloves should be surgical gloves that match the size of your hand |
| 6 | No laser signal on the Aligna 4D control software | Laser switch is off | Make sure that the laser switch is turned on with the main unit and the ZEN software |
| 9 | Mice die during anesthesia | The level of anesthesia is too high | Decrease the concentration of anesthesia as soon as the mouse shows loss of righting reflex |
| 10 | Mice regain consciousness during anesthesia | The level of anesthesia is too low | Confirm the concentration of anesthesia; administer the reagents again after a brief pause |
| 15 | No heart rate is measured | The monitoring probe is mispositioned | Make sure that the monitoring probe is in the appropriate place |
| 17 | The cover glass falls off | The cover glass does not hold on the suction device | Put water droplets on the tip of the suction device and then place the cover glass on it |

Timing

- Step 1, infection: 10–20 min
- Steps 2–7, starting up the imaging system equipment: 20–30 min
- Steps 8–22, anesthesia and surgical preparation for imaging: 21–29 min
- Steps 23–26, data acquisition and image analyses: 2–6 h per sample (depending on the number of samples, fluorescent colors, and acquired frames)

Anticipated results

The imaging system described in this protocol enables the observation of the behavior of virus-infected cells and immune cells in infected lungs in real time. Typical images of influenza virus-infected lung are shown in Fig. 5a and Supplementary Video 2. When observing while using a multicolor fluorescent label, it is easier to analyze the detected images if the brightness level of each fluorophore is adjusted to make them similar. It is better to choose fluorescent dyes or proteins that possess high fluorescence stability for long-term observations (Tables 2, 4 and 5). We have found that use of MA-Cerulean-viruses or MA-Venus-viruses for infection produces influenza virus-infected cells with sufficient brightness (Table 3). For labeling immune cells and alveolar cells, we have achieved good results by using the fluorochrome phycoerythrin (PE) for antibody staining and Rosa^{tdTomato}⁴² or -mTFP1³³ mice that were crossed with cell-specific Cre-expressing mice. If using reporter mice expressing a fluorescent protein such as GFP, which is regulated by an endogenous promoter, the expression level of the fluorescent protein should be confirmed. To visualize the lung structure, we use Texas-Red dextran or Qtracker 655 Vascular Labels for the red to far-infrared channel.




Fig. 5 | In vivo multicolor imaging of influenza virus-infected lungs. **a**, Catchup^{I^{VM}-red} mice were intranasally infected with 10^5 PFU of MA-Venus-H5N1 or MA-Venus-PR8 virus and observed at 4 d post-infection. Fluorescent dextran (blue) was intravenously administered to visualize the lung architecture. Red and green indicate neutrophils and virus-infected cells, respectively. **b**, $Ly6g^{Cre/+};R26^{mTFPI/+}$ mice were intranasally infected with 10^5 PFU of MA-Venus-PR8 virus and observed at 7 d post-infection. PE-conjugated anti-mouse Ly-6G antibody (red) and fluorescent dextran (white) were intravenously administered to visualize the vascular neutrophils and lung architectures, respectively. Green indicates virus-infected cells. Blue indicates both infiltrating (arrowheads) and vascular neutrophils (arrow). **c**, $Ly6g^{Cre/+};R26^{tdTomato/+};Cx3cr1^{GFP/+}$ mice were intranasally infected with 10^5 PFU of MA-Venus-PR8 virus and observed at 5 d post-infection. Fluorescent dextran (white) was intravenously administered to visualize the lung architecture. Red, green, and blue indicate neutrophils, monocytes, and virus-infected cells, respectively. The yellow arrowhead and arrow indicate a neutrophil and a monocyte, respectively, in contact. AB, antibody.

Influenza virus-infected lungs are infiltrated by numerous immune cells, including neutrophils and monocytes^{43–45}. An immune cell-specific reporter mouse line can be used to visualize cells infiltrating the alveoli and cells in blood vessels, whereas it is preferable to label intravascular cells by intravenous administration of fluorochrome-conjugated antibodies^{5,46,47}. Consistent with previous reports, intravenously injected antibodies will label only the cells in contact with the blood flow and not those in extravascular regions under our experimental conditions⁵. By administering a fluorescently labeled antibody against neutrophils into neutrophil reporter mice, we can observe the behavior of both the neutrophils infiltrating the influenza-infected lungs and the neutrophils in blood vessels separately (Fig. 5b). To observe the interaction between different kinds of infiltrating immune




Fig. 6 | Co-infection imaging of influenza virus-infected lungs. B6 mice were intranasally infected with 10^5 PFU of MA-Venus-H5N1 and MA-Cerulean-H5N1, or MA-Venus-PR8 and MA-Cerulean-PR8 viruses and observed at 3 d (H5N1) or 4 d (PR8) post-infection. Fluorescent dextran (white) was intravenously administered to visualize the lung architecture. Red and green indicate MA-Cerulean-virus-infected cells (yellow arrows) and MA-Venus-virus-infected cells (white arrows), respectively. The yellow arrowheads indicate cells co-infected with MA-Cerulean-virus and MA-Venus-virus. Scale bar, 50 μ m.

cells, such as neutrophils and monocytes, double-reporter mice expressing fluorescent proteins with different spectra but similar brightness have a major advantage (Fig. 5c and Supplementary Video 3).

Co-infection of the host with different strains of influenza virus can lead to the emergence of reassortant viruses. By infecting mice with Color-flu viruses that produce different fluorescence spectra, we detected alveolar epithelial cells that simultaneously expressed two fluorescent proteins in vivo (Fig. 6). Visualization of co-infected cells might enable us to better understand the reassortment process of influenza viruses in vivo.

In summary, the use of this in vivo imaging system for infected animal and multicolor imaging enables us to analyze pathology and immune cell dynamics at the cellular level, which would not be possible by using conventional histopathology methods. This imaging system thus provides a novel and useful approach for investigating viral pathogenicity.

Reporting Summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The data that support this study are available from the corresponding author upon reasonable request.

Code availability

The MATLAB scripts are available at https://github.com/KawaokaLab/Ueki_PNAS_2018.

References

- Tran, V., Moser, L. A., Poole, D. S. & Mehle, A. Highly sensitive real-time in vivo imaging of an influenza reporter virus reveals dynamics of replication and spread. *J. Virol.* **87**, 13321–13329 (2013).
- Veldhuis Kroeze, E. J. et al. Consecutive CT in vivo lung imaging as quantitative parameter of influenza vaccine efficacy in the ferret model. *Vaccine* **30**, 7391–7394 (2012).
- Denk, W., Holt, J. R., Shepherd, G. M. & Corey, D. P. Calcium imaging of single stereocilia in hair cells: localization of transduction channels at both ends of tip links. *Neuron* **15**, 1311–1321 (1995).
- Choi, M., Kwok, S. J. & Yun, S. H. In vivo fluorescence microscopy: lessons from observing cell behavior in their native environment. *Physiology* **30**, 40–49 (2015).
- Ueki, H. et al. In vivo imaging of the pathophysiological changes and neutrophil dynamics in influenza virus-infected mouse lungs. *Proc. Natl Acad. Sci USA* **115**, E6622–E6629 (2018).
- West, J. B. Marcello Malpighi and the discovery of the pulmonary capillaries and alveoli. *Am. J. Physiol. Lung Cell Mol. Physiol.* **304**, L383–L390 (2013).
- Looney, M. R. & Bhattacharya, J. Live imaging of the lung. *Annu. Rev. Physiol.* **76**, 431–445 (2014).
- Looney, M. R. & Headley, M. B. Live imaging of the pulmonary immune environment. *Cell. Immunol.*, <https://doi.org/10.1016/j.cellimm.2018.09.007> (2018).
- Macgregor, R. G. Examination of the pulmonary circulation with the microscope. *J. Physiol.* **80**, 65–77 (1933).
- Hasegawa, A. et al. Color-coded real-time cellular imaging of lung T-lymphocyte accumulation and focus formation in a mouse asthma model. *J. Allergy Clin. Immunol.* **125**, 461–468.e6 (2010).

11. Mitsuoka, H. et al. Pathophysiological role of endothelins in pulmonary microcirculatory disorders due to intestinal ischemia and reperfusion. *J. Surg. Res.* **87**, 143–151 (1999).
12. Tabuchi, A., Mertens, M., Kuppe, H., Pries, A. R. & Kuebler, W. M. Intravital microscopy of the murine pulmonary microcirculation. *J. Appl. Physiol.* **104**, 338–346 (2008).
13. Veith, N. T. et al. Surfactant protein A mediates pulmonary clearance of *Staphylococcus aureus*. *Respir. Res.* **15**, 85 (2014).
14. Kreisel, D. et al. In vivo two-photon imaging reveals monocyte-dependent neutrophil extravasation during pulmonary inflammation. *Proc. Natl Acad. Sci. USA* **107**, 18073–18078 (2010).
15. Spahn, J. H. et al. DAP12 expression in lung macrophages mediates ischemia/reperfusion injury by promoting neutrophil extravasation. *J. Immunol.* **194**, 4039–4048 (2015).
16. Looney, M. R. et al. Stabilized imaging of immune surveillance in the mouse lung. *Nat. Methods* **8**, 91–96 (2011).
17. Presson, R. G. Jr et al. Two-photon imaging within the murine thorax without respiratory and cardiac motion artifact. *Am. J. Pathol.* **179**, 75–82 (2011).
18. Headley, M. B. et al. Visualization of immediate immune responses to pioneer metastatic cells in the lung. *Nature* **531**, 513–517 (2016).
19. Lefrancais, E. et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. *Nature* **544**, 105–109 (2017).
20. Benson, R. A., Lawton, J. C. & MacLeod, M. K. T cell response in the lung following influenza virus infection. *Methods Mol. Biol.* **1591**, 235–248 (2017).
21. Lim, K. et al. Neutrophil trails guide influenza-specific CD8⁺ T cells in the airways. *Science* **349**, aaa4352 (2015).
22. Lambert Emo, K. et al. Live imaging of influenza infection of the trachea reveals dynamic regulation of CD8⁺ T cell motility by antigen. *PLoS Pathog.* **12**, e1005881 (2016).
23. Palomino-Segura, M., Virgilio, T., Morone, D., Pizzagalli, D. U. & Gonzalez, S. F. Imaging cell interaction in tracheal mucosa during influenza virus infection using two-photon intravital microscopy. *J. Vis. Exp.* **2018**, e58355, <https://doi.org/10.3791/58355> (2018).
24. Matheu, M. P. et al. Three phases of CD8 T cell response in the lung following H1N1 influenza infection and sphingosine 1 phosphate agonist therapy. *PLoS One* **8**, e58033 (2013).
25. Fukuyama, S. et al. Multi-spectral fluorescent reporter influenza viruses (Color-flu) as powerful tools for in vivo studies. *Nat. Commun.* **6**, 6600 (2015).
26. Zhao, D. et al. Molecular determinants of virulence and stability of a reporter-expressing H5N1 influenza A virus. *J. Virol.* **89**, 11337–11346 (2015).
27. Katsura, H. et al. Amino acid changes in PB2 and HA affect the growth of a recombinant influenza virus expressing a fluorescent reporter protein. *Sci. Rep.* **6**, 19933 (2016).
28. Thornton, E. E., Krummel, M. F. & Looney, M. R. Live imaging of the lung. *Curr. Protoc. Cytom.* **60**, 12.28.1–12.28.12 (2012).
29. Sakai, K. & Miyazaki, J. A transgenic mouse line that retains Cre recombinase activity in mature oocytes irrespective of the cre transgene transmission. *Biochem. Biophys. Res. Commun.* **237**, 318–324 (1997).
30. Faust, N., Varas, F., Kelly, L. M., Heck, S. & Graf, T. Insertion of enhanced green fluorescent protein into the lysozyme gene creates mice with green fluorescent granulocytes and macrophages. *Blood* **96**, 719–726 (2000).
31. Rock, J. R. et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. *Proc. Natl Acad. Sci. USA* **108**, E1475–1483 (2011).
32. Hasenberg, A. et al. Catchup: a mouse model for imaging-based tracking and modulation of neutrophil granulocytes. *Nat. Methods* **12**, 445–452 (2015).
33. Imayoshi, I. et al. A multifunctional teal-fluorescent Rosa26 reporter mouse line for Cre- and Flp-mediated recombination. *Neurosci. Res.* **73**, 85–91 (2012).
34. Tinevez, J. Y. et al. TrackMate: an open and extensible platform for single-particle tracking. *Methods* **115**, 80–90 (2017).
35. Tate, M. D. et al. The role of neutrophils during mild and severe influenza virus infections of mice. *PLoS One* **6**, e17618 (2011).
36. Narasaraju, T. et al. Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis. *Am. J. Pathol.* **179**, 199–210 (2011).
37. Reilly, E. C., Lambert-Emo, K. & Topham, D. J. The effects of acute neutrophil depletion on resolution of acute influenza infection, establishment of tissue resident memory (TRM), and heterosubtypic immunity. *PLoS One* **11**, e0164247 (2016).
38. Yipp, B. G. & Kubes, P. Antibodies against neutrophil LY6G do not inhibit leukocyte recruitment in mice in vivo. *Blood* **121**, 241–242 (2013).
39. Wang, J. X. et al. Ly6G ligation blocks recruitment of neutrophils via a β 2-integrin-dependent mechanism. *Blood* **120**, 1489–1498 (2012).
40. Garini, Y., Young, I. T. & McNamara, G. Spectral imaging: principles and applications. *Cytom. A* **69**, 735–747 (2006).
41. Levenson, R. M. & Mansfield, J. R. Multispectral imaging in biology and medicine: slices of life. *Cytom. A* **69**, 748–758 (2006).

42. Madisen, L. et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. *Nat. Neurosci.* **13**, 133–140 (2010).
43. Braciale, T. J., Sun, J. & Kim, T. S. Regulating the adaptive immune response to respiratory virus infection. *Nat. Rev. Immunol.* **12**, 295–305 (2012).
44. Brandes, M., Klauschen, F., Kuchen, S. & Germain, R. N. A systems analysis identifies a feedforward inflammatory circuit leading to lethal influenza infection. *Cell* **154**, 197–212 (2013).
45. Iwasaki, A. & Pillai, P. S. Innate immunity to influenza virus infection. *Nat. Rev. Immunol.* **14**, 315–328 (2014).
46. Anderson, K. G. et al. Intravascular staining for discrimination of vascular and tissue leukocytes. *Nat. Protoc.* **9**, 209–222 (2014).
47. Patel, B. V., Tatham, K. C., Wilson, M. R., O’Dea, K. P. & Takata, M. In vivo compartmental analysis of leukocytes in mouse lungs. *Am. J. Physiol. Lung Cell Mol. Physiol.* **309**, L639–652 (2015).
48. Hall, H. L. A study of the pulmonary circulation by the transillumination method. *Am. J. Physiol.* **72**, 446–457 (1925).
49. Wagner, W. W. Jr & Latham, L. P. Pulmonary capillary recruitment during airway hypoxia in the dog. *J. Appl. Physiol.* **39**, 900–905 (1975).
50. Wearn, J. T., Barr, J. S. & German, W. J. The behavior of the arterioles and capillaries of the lung. *Exp. Biol. Med.* **24**, 114–115 (1926).
51. Wagner, W. W. Jr, Latham, L. P. & Capen, R. L. Capillary recruitment during airway hypoxia: role of pulmonary artery pressure. *J. Appl. Physiol. Respir. Environ. Exerc. Physiol.* **47**, 383–387 (1979).
52. Olkon, D. M. & Joannides, M. Capillaroscopic appearance of the pulmonary alveoli in the living dog. *Anat. Rec.* **45**, 121–127 (1930).
53. Capen, R. L., Latham, L. P. & Wagner, W. W. Jr. Diffusing capacity of the lung during hypoxia: role of capillary recruitment. *J. Appl. Physiol. Respir. Environ. Exerc. Physiol.* **50**, 165–171 (1981).
54. Capen, R. L. & Wagner, W. W. Jr. Intrapulmonary blood flow redistribution during hypoxia increases gas exchange surface area. *J. Appl. Physiol. Respir. Environ. Exerc. Physiol.* **52**, 1575–1580 (1982).
55. Wearn, J. T. et al. The normal behavior of the pulmonary blood vessels with observations on the intermittence of the flow of blood in the arterioles and capillaries. *Am. J. Physiol.* **109**, 236–256 (1934).
56. Groh, J., Kuhnle, G. E., Kuebler, W. M. & Goetz, A. E. An experimental model for simultaneous quantitative analysis of pulmonary micro- and macrocirculation during unilateral hypoxia in vivo. *Res. Exp. Med.* **192**, 431–441 (1992).
57. Terry, R. J. A thoracic window for observation of the lung in a living animal. *Science* **90**, 43–44 (1939).
58. Wagner, W. W. Jr. & Filley, G. F. Microscopic observation of the lung in vivo. *Vasc. Dis.* **2**, 229–241 (1965).
59. Tabuchi, A. et al. Precapillary oxygenation contributes relevantly to gas exchange in the intact lung. *Am. J. Respir. Crit. Care Med.* **188**, 474–481 (2013).
60. Wagner, W. W. Jr. Pulmonary microcirculatory observations in vivo under physiological conditions. *J. Appl. Physiol.* **26**, 375–377 (1969).
61. Wagner, W. W. Jr, Latham, L. P., Gillespie, M. N., Guenther, J. P. & Capen, R. L. Direct measurement of pulmonary capillary transit times. *Science* **218**, 379–381 (1982).
62. Mitsuoka, H. et al. Intravital laser confocal microscopy of pulmonary edema resulting from intestinal ischemia-reperfusion injury in the rat. *Crit. Care Med.* **27**, 1862–1868 (1999).
63. Lien, D. C. et al. Physiological neutrophil sequestration in the lung: visual evidence for localization in capillaries. *J. Appl. Physiol.* **62**, 1236–1243 (1987).
64. Bhattacharya, S., Glucksberg, M. R. & Bhattacharya, J. Measurement of lung microvascular pressure in the intact anesthetized rabbit by the micropuncture technique. *Circ. Res.* **64**, 167–172 (1989).
65. Kreisel, D. et al. Emergency granulopoiesis promotes neutrophil-dendritic cell encounters that prevent mouse lung allograft acceptance. *Blood* **118**, 6172–6182 (2011).
66. Okada, O. et al. Capillary perfusion patterns in single alveolar walls. *J. Appl. Physiol.* **72**, 1838–1844 (1992).
67. Kuhnle, G. E., Leipfinger, F. H. & Goetz, A. E. Measurement of microhemodynamics in the ventilated rabbit lung by intravital fluorescence microscopy. *J. Appl. Physiol.* **74**, 1462–1471 (1993).
68. Zheng, Z. et al. Donor pulmonary intravascular nonclassical monocytes recruit recipient neutrophils and mediate primary lung allograft dysfunction. *Sci. Transl. Med.* **9**, aal4508 (2017).
69. Kuebler, W. M., Kuhnle, G. E., Groh, J. & Goetz, A. E. Leukocyte kinetics in pulmonary microcirculation: intravital fluorescence microscopic study. *J. Appl. Physiol.* **76**, 65–71 (1994).
70. Schmidt, E. P. et al. The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. *Nat. Med.* **18**, 1217–1223 (2012).
71. Okada, O., Presson, R. G. Jr, Godbey, P. S., Capen, R. L. & Wagner, W. W. Jr. Temporal capillary perfusion patterns in single alveolar walls of intact dogs. *J. Appl. Physiol.* **76**, 380–386 (1994).
72. Ortiz-Munoz, G. et al. Aspirin-triggered 15-epi-lipoxin A4 regulates neutrophil-platelet aggregation and attenuates acute lung injury in mice. *Blood* **124**, 2625–2634 (2014).
73. Gebb, S. A. et al. Sites of leukocyte sequestration in the pulmonary microcirculation. *J. Appl. Physiol.* **79**, 493–497 (1995).
74. Chong, S. Z. et al. CXCR4 identifies transitional bone marrow premonocytes that replenish the mature monocyte pool for peripheral responses. *J. Exp. Med.* **213**, 2293–2314 (2016).
75. Kuebler, W. M., Kuhnle, G. E., Groh, J. & Goetz, A. E. Contribution of selectins to leukocyte sequestration in pulmonary microvessels by intravital microscopy in rabbits. *J. Physiol.* **501**, 375–386 (1997).

76. Bennewitz, M. F. et al. Lung vaso-occlusion in sickle cell disease mediated by arteriolar neutrophil-platelet microemboli. *JCI Insight* **2**, e89761 (2017).
77. Kuebler, W. M., Kuhnle, G. E. & Goetz, A. E. Leukocyte margination in alveolar capillaries: interrelationship with functional capillary geometry and microhemodynamics. *J. Vasc. Res.* **36**, 282–288 (1999).
78. Park, I. et al. Neutrophils disturb pulmonary microcirculation in sepsis-induced acute lung injury. *Eur. Respir. J.* **53**, 1800786 (2019).
79. Eichhorn, M. E., Ney, L., Massberg, S. & Goetz, A. E. Platelet kinetics in the pulmonary microcirculation in vivo assessed by intravital microscopy. *J. Vasc. Res.* **39**, 330–339 (2002).
80. McCormack, D. G. et al. Pulmonary microvascular changes during sepsis: evaluation using intravital videomicroscopy. *Microvasc. Res.* **60**, 131–140 (2000).
81. Lamm, W. J., Bernard, S. L., Wagner, W. W. Jr & Glenny, R. W. Intravital microscopic observations of 15-microm microspheres lodging in the pulmonary microcirculation. *J. Appl. Physiol.* **98**, 2242–2248 (2005).
82. Park, I. et al. Intravital imaging of a pulmonary endothelial surface layer in a murine sepsis model. *Biomed. Opt. Express* **9**, 2383–2393 (2018).
83. Yang, Y., Yang, G. & Schmidt, E. P. In vivo measurement of the mouse pulmonary endothelial surface layer. *J. Vis. Exp.* **2013**, e50322, <https://doi.org/10.3791/50322> (2013).
84. Cortez-Retamozo, V. et al. Real-time assessment of inflammation and treatment response in a mouse model of allergic airway inflammation. *J. Clin. Invest.* **118**, 4058–4066 (2008).
85. Tschernig, T. et al. Direct visualisation of microparticles in the living lung. *Exp. Toxicol. Pathol.* **65**, 883–886 (2013).
86. Thornton, E. E. et al. Spatiotemporally separated antigen uptake by alveolar dendritic cells and airway presentation to T cells in the lung. *J. Exp. Med.* **209**, 1183–1199 (2012).
87. Fiore, D. et al. Two-photon intravital imaging of lungs during anthrax infection reveals long-lasting macrophage-dendritic cell contacts. *Infect. Immun.* **82**, 864–872 (2014).
88. Chojnacki, A. et al. Intravital imaging allows real-time characterization of tissue resident eosinophils. *Commun. Biol.* **2**, 181 (2019).
89. Bennewitz, M. F., Watkins, S. C. & Sundd, P. Quantitative intravital two-photon excitation microscopy reveals absence of pulmonary vaso-occlusion in unchallenged sickle cell disease mice. *Intravital* **3**, e29748 (2014).
90. Preu, L. et al. Initial host response to bacteria in the murine lung differs between *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Streptococcus pneumoniae*. *Inflammation* **39**, 513–517 (2016).
91. Thanabalasuriar, A., Neupane, A. S., Wang, J., Krummel, M. F. & Kubes, P. iNKT cell emigration out of the lung vasculature requires neutrophils and monocyte-derived dendritic cells in inflammation. *Cell Reps.* **16**, 3260–3272 (2016).
92. Fingar, V. H., Taber, S. W. & Wieman, T. J. A new model for the study of pulmonary microcirculation: determination of pulmonary edema in rats. *J. Surg. Res.* **57**, 385–393 (1994).
93. Yipp, B. G. et al. The lung is a host defense niche for immediate neutrophil-mediated vascular protection. *Sci. Immunol.* **2**, eaam8929 (2017).
94. Schneider, P., Foitzik, T., Kahrau, S., Podufal, A. & Buhr, H. J. An experimental rat model for studying pulmonary microcirculation by in vivo videomicroscopy. *Microvasc. Res.* **62**, 421–434 (2001).
95. Thanabalasuriar, A. et al. Bispecific antibody targets multiple *Pseudomonas aeruginosa* evasion mechanisms in the lung vasculature. *J. Clin. Invest.* **127**, 2249–2261 (2017).
96. Mertens, M. et al. Alveolar dynamics in acute lung injury: heterogeneous distension rather than cyclic opening and collapse. *Crit. Care Med.* **37**, 2604–2611 (2009).
97. Lefrancais, E., Mallavia, B., Zhuo, H., Calfee, C. S. & Looney, M. R. Maladaptive role of neutrophil extracellular traps in pathogen-induced lung injury. *JCI Insight* **3**, e98178 (2018).
98. Lee, E. K. S. et al. Leukotriene B₄-mediated neutrophil recruitment causes pulmonary capillaritis during lethal fungal sepsis. *Cell Host Microbe* **23**, 121–133.e124 (2018).
99. Surewaard, B. G. J. et al. α -Toxin induces platelet aggregation and liver injury during *Staphylococcus aureus* sepsis. *Cell Host Microbe* **24**, 271–284.e273 (2018).
100. Devi, S. et al. Neutrophil mobilization via plerixafor-mediated CXCR4 inhibition arises from lung demargination and blockade of neutrophil homing to the bone marrow. *J. Exp. Med.* **210**, 2321–2336 (2013).
101. Caudrillier, A., Mallavia, B., Rouse, L., Marschner, S. & Looney, M. R. Transfusion of human platelets treated with mirasol pathogen reduction technology does not induce acute lung injury in mice. *PLoS One* **10**, e0133022 (2015).
102. Funakoshi, N. et al. A new model of lung metastasis for intravital studies. *Microvasc. Res.* **59**, 361–367 (2000).
103. Wang, J. et al. Visualizing the function and fate of neutrophils in sterile injury and repair. *Science* **358**, 111–116 (2017).
104. Entenberg, D. et al. In vivo subcellular resolution optical imaging in the lung reveals early metastatic proliferation and motility. *Intravital* **4**(3), 1–11 (2015).
105. Chakarov, S. et al. Two distinct interstitial macrophage populations coexist across tissues in specific sub-tissular niches. *Science* **363**, aau0964 (2019).
106. Hanna, R. N. et al. Patrolling monocytes control tumor metastasis to the lung. *Science* **350**, 985–990 (2015).

107. Puttur, F. et al. Pulmonary environmental cues drive group 2 innate lymphoid cell dynamics in mice and humans. *Sci. Immunol.* **4**, eaav7638 (2019).
108. Rodriguez-Tirado, C. et al. Long-term high-resolution intravital microscopy in the lung with a vacuum stabilized imaging window. *J. Vis. Exp.* **2016**, e54603, <https://doi.org/10.3791/54603> (2016).
109. Park, J. et al. Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps. *Sci. Transl. Med.* **8**, 361ra138 (2016).
110. Entenberg, D. et al. A permanent window for the murine lung enables high-resolution imaging of cancer metastasis. *Nat. Methods* **15**, 73–80 (2018).
111. Hadjantonakis, A. K., Macmaster, S. & Nagy, A. Embryonic stem cells and mice expressing different GFP variants for multiple non-invasive reporter usage within a single animal. *BMC Biotechnol.* **2**, 11 (2002).
112. Srinivas, S. et al. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. *BMC Dev. Biol.* **1**, 4 (2001).
113. Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L. & Luo, L. A global double-fluorescent Cre reporter mouse. *Genesis* **45**, 593–605 (2007).
114. Jung, S. et al. In vivo depletion of CD11c⁺ dendritic cells abrogates priming of CD8⁺ T cells by exogenous cell-associated antigens. *Immunity* **17**, 211–220 (2002).
115. Caton, M. L., Smith-Raska, M. R. & Reizis, B. Notch-RBP-J signaling controls the homeostasis of CD8⁺ dendritic cells in the spleen. *J. Exp. Med.* **204**, 1653–1664 (2007).
116. Satpathy, A. T. et al. Zbtb46 expression distinguishes classical dendritic cells and their committed progenitors from other immune lineages. *J. Exp. Med.* **209**, 1135–1152 (2012).
117. Loschko, J. et al. Absence of MHC class II on cDCs results in microbial-dependent intestinal inflammation. *J. Exp. Med.* **213**, 517–534 (2016).
118. Sancho, D. et al. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. *Nature* **458**, 899–903 (2009).
119. Sasmono, R. T. et al. A macrophage colony-stimulating factor receptor-green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse. *Blood* **101**, 1155–1163 (2003).
120. Jung, S. et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. *Mol. Cell. Biol.* **20**, 4106–4114 (2000).
121. Yona, S. et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. *Immunity* **38**, 79–91 (2013).
122. Aghajani, K., Keerthivasan, S., Yu, Y. & Gounari, F. Generation of CD4CreER(T2) transgenic mice to study development of peripheral CD4-T-cells. *Genesis* **50**, 908–913 (2012).
123. Maekawa, Y. et al. Notch2 integrates signaling by the transcription factors RBP-J and CREB1 to promote T cell cytotoxicity. *Nat. Immunol.* **9**, 1140–1147 (2008).
124. Rickert, R. C., Roes, J. & Rajewsky, K. B lymphocyte-specific, Cre-mediated mutagenesis in mice. *Nucleic Acids Res.* **25**, 1317–1318 (1997).
125. Sullivan, B. M. et al. Genetic analysis of basophil function in vivo. *Nat. Immunol.* **12**, 527–535 (2011).
126. Gazit, R. et al. Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. *Nat. Immunol.* **7**, 517–523 (2006).
127. Vanderbilt, J. N. et al. High-efficiency type II cell-enhanced green fluorescent protein expression facilitates cellular identification, tracking, and isolation. *Am. J. Respir. Cell Mol. Biol.* **53**, 14–21 (2015).
128. Cutrale, F. et al. Hyperspectral phasor analysis enables multiplexed 5D in vivo imaging. *Nat. Methods* **14**, 149–152 (2017).
129. Inglada, J. & Christophe, E. The Orfeo Toolbox remote sensing image processing software. *IEEE Int. Geosci. Remote Sens. Symp.* **4**, IV-733–IV-736 (2009).
130. Neher, R. & Neher, E. Optimizing imaging parameters for the separation of multiple labels in a fluorescence image. *J. Microsc.* **213**, 46–62 (2004).
131. Zimmermann, T., Rietdorf, J., Girod, A., Georget, V. & Pepperkok, R. Spectral imaging and linear un-mixing enables improved FRET efficiency with a novel GFP2-YFP FRET pair. *FEBS Lett.* **531**, 245–249 (2002).
132. Neher, R. A. et al. Blind source separation techniques for the decomposition of multiply labeled fluorescence images. *Biophys. J.* **96**, 3791–3800 (2009).
133. Thirion, J. P. Image matching as a diffusion process: an analogy with Maxwell's demons. *Med. Image Anal.* **2**, 243–260 (1998).
134. Vercauteren, T., Pennec, X., Perchant, A. & Ayache, N. Diffeomorphic demons: efficient non-parametric image registration. *NeuroImage* **45**, S61–S72 (2009).
135. Lee, S., Vinegoni, C., Sebas, M. & Weissleder, R. Automated motion artifact removal for intravital microscopy, without a priori information. *Sci. Rep.* **4**, 4507 (2014).
136. Rueckert, D. et al. Nonrigid registration using free-form deformations: application to breast MR images. *IEEE Trans. Med. Imaging* **18**, 712–721 (1999).
137. Dunn, K. W., Lorenz, K. S., Salama, P. & Delp, E. J. IMART software for correction of motion artifacts in images collected in intravital microscopy. *Intravital* **3**, e28210 (2014).
138. Soulet, D., Pare, A., Coste, J. & Lacroix, S. Automated filtering of intrinsic movement artifacts during two-photon intravital microscopy. *PLoS One* **8**, e53942 (2013).
139. Warren, S. C. et al. Removing physiological motion from intravital and clinical functional imaging data. *eLife* **7**, 35800.002 (2018).

140. Hilsenbeck, O. et al. Software tools for single-cell tracking and quantification of cellular and molecular properties. *Nat. Biotechnol.* **34**, 703–706 (2016).
141. Carpenter, A. E. et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. *Genome Biol.* **7**, R100 (2006).
142. de Chaumont, F. et al. Icy: an open bioimage informatics platform for extended reproducible research. *Nat. Methods* **9**, 690–696 (2012).

Acknowledgements

We thank S. Watson for editing the manuscript. We thank K. Iwatsuki-Horimoto, L. Wu, S. Fukuyama, Y. Matsuzawa, and K. Miyake (The University of Tokyo); M. Ishii, H. Mizuno, and J. Kikuta (Osaka University Graduate School of Medicine); and H. Ueno (Kansai Medical University) for research assistance. We thank J. Miyazaki (Osaka University Graduate School of Medicine), T. Graf (Albert Einstein College of Medicine), B. L. M. Hogan (Duke University Medical Center), I. Imayoshi (Kyoto University), and R. G. Webster (St. Jude Children's Research Hospital) for providing animals and a cell line. This research was supported by Strategic Basic Research Programs from the Japan Science and Technology Agency (JST); Leading Advanced Projects for Medical Innovation (LEAP) from the Japan Agency for Medical Research and Development (AMED) (JP18am001007); Grants-in-Aid for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Science, Sports, and Technology (MEXT) of Japan (16H06429, 16K21723, and 16H06434); the Japan Initiative for Global Research Network on Infectious Diseases (J-GRID) from the MEXT of Japan and from AMED (JP19fm0108006); the e-ASIA Joint Research Program from AMED (JP17jm0210042); the Research Program on Emerging and Re-emerging Infectious Diseases from AMED (JP19fk0108031); the NIAID-funded Center for Research on Influenza Pathogenesis (CRIP) (HHSN272201400008C); the fund for the Promotion of Joint International Research (Fostering Joint International Research (B)) from the Japan Society for the Promotion of Science (JSPS) (JP18KK0225); MEXT KAKENHI (18K14580); and JSPS KAKENHI (P16416).

Author contributions

H.U., D.Z., and Y.K. designed the method and performed the experiments. M.G. provided a mouse line. H.U., I.-H.W., and Y.K. wrote the manuscript.

Competing interests

Y.K. is a founder of FluGen and has received speaker's honoraria from Toyama Chemical and Astellas and grant support from Chugai Pharmaceuticals, Daiichi Sankyo Pharmaceutical, Toyama Chemical, Tauns Laboratories, Otsuka Pharmaceutical, and Kyoritsu Seiyaku.

Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41596-019-0275-y>.

Correspondence and requests for materials should be addressed to Y.K.

Peer review information *Nature Protocols* thanks Megan MacLeod and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 4 September 2019; Accepted: 3 December 2019;

Published online: 29 January 2020

Related links

Key references using this protocol

Fukuyama, S. et al. *Nat. Commun.* **6**, 6600 (2015): <https://doi.org/10.1038/ncomms7600>

Ueki, H. et al. *Proc. Natl Acad. Sci. USA* **115**, E6622–E6629 (2018): <https://doi.org/10.1073/pnas.1806265115>

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

To efficiently excite multiple fluorescent proteins and fluorescent dyes simultaneously, the wavelength of the infrared laser was set at 910 nm. All fluorescent spectra between 410 and 695 nm wavelengths were detected using a 20x water immersion lens (Carl Zeiss AG, Germany) and the signals were recorded in lambda image stacks.

Data analysis

We use the linear unmixing module of ZEN software for separating spectrum data. Unmixed time-series stacks are subjected to image registration to correct for tissue drifts and respiratory artefacts. A reference channel is required for determining the shift and distortion of the objects. In our studies, we employ time-series stacks of blood vessels or collagens for such use, as their localizations are constant over time without significant changes in shapes or structures during the observation.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The data that support this study are available from the corresponding author upon reasonable request.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

| | |
|-----------------|---|
| Sample size | Only one sample was shown as a representative example that can be obtained by using the imaging protocol. |
| Data exclusions | No data was excluded since one representative image was shown. |
| Replication | No repeated measurements were performed in this paper since one image has been shown as a representative image by using the imaging protocol. |
| Randomization | No randomization is included in this paper since one image has been shown as a representative image by using the imaging protocol. |
| Blinding | Blinding was not relevant to this study which is describing a imaging protocol and anticipated results. |

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

| n/a | Involvement in the study |
|-------------------------------------|---|
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Antibodies |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Eukaryotic cell lines |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Palaeontology |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Animals and other organisms |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Human research participants |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Clinical data |

Methods

| n/a | Involvement in the study |
|-------------------------------------|---|
| <input checked="" type="checkbox"/> | <input type="checkbox"/> ChIP-seq |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Flow cytometry |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> MRI-based neuroimaging |

Antibodies

| | |
|-----------------|--|
| Antibodies used | FITC-conjugated anti-mouse Ly-6G antibody (BioLegend Cat# 127606, RRID:AB_1236494). Alexa FluorR 488-conjugated anti-mouse Ly-6G antibody (BioLegend Cat# 127626, RRID:AB_2561340). DyLightR 488-conjugated anti-mouse Ly-6G antibody (Leinco Technologies, Cat# L287, RRID:AB_2810281). PE-conjugated anti-mouse Ly-6G antibody (BD Biosciences Cat# 551461, RRID:AB_394208). Alexa FluorR 594-conjugated anti-mouse Ly-6G antibody (BioLegend Cat# 127636, RRID:AB_2563207). Alexa FluorR 647-conjugated anti-mouse Ly-6G antibody (BBioLegend Cat# 127610, RRID:AB_1134159). |
| Validation | All antibodies used are commercialized and the fluorescence has been tested in this study. The Information is included in Table 4. |

Eukaryotic cell lines

Policy information about [cell lines](#)

| | |
|--|--|
| Cell line source(s) | Madin-Darby canine kidney (MDCK) cells. |
| Authentication | None of the cell lines used have been authenticated. |
| Mycoplasma contamination | All used cell stocks tested negative for mycoplasma. |
| Commonly misidentified lines (See ICLAC register) | No commonly misidentified cell lines were used. |

Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

| | |
|-------------------------|--|
| Laboratory animals | Six-ten-week-old C57BL/6 mice (Japan SLC, Inc.) and transgenic mouse lines were used in this study. All animal care and experiments conformed to the guidelines for animal experiments of the University of Tokyo, and were approved by the animal research committee of the University of Tokyo (PA17-31 and PA17-17). All in vivo imaging studies were performed in the biosafety level 3 facility at the University of Tokyo (Tokyo, Japan), which is approved for such use by the Ministry of Agriculture, Forestry, and Fisheries of Japan. |
| Wild animals | Not applicable. |
| Field-collected samples | Not applicable. |
| Ethics oversight | All experiments with mice were performed in accordance with the University of Tokyo's Regulations for Animal Care and Use and were approved by the Animal Experiment Committee of the Institute of Medical Science, the University of Tokyo. |

Note that full information on the approval of the study protocol must also be provided in the manuscript.